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Abstract
The interactions between Alzheimer’s disease (AD) and ischemic stroke pathology are of
key interest in the development of post-stroke cognitive decline. While clinical and
experimental studies have suggested an interaction, the mechanisms whereby these
conditions interact to worsen cognition haven’t been fully revealed. This study aimed to
combine rodent models of AD and stroke in an aged rat and assess the behavioural and
histological outcomes. An injection of endothelin-1 (ET-1), a potent vasoconstrictor into
the basal ganglia of a rat with human amyloid precursor protein (hAPP) overexpression
(F344Tg) was followed up 3 months later to assess behavioural flexibility, memory and
anxiety phenotypes, followed by assessment of infarct size and microglia and astrocyte
activity. At the chronic post-injury time-point, impaired behavioural flexibility was
observed in F344Tg/ET-1 combined rats, while anxiety-like phenotypes, deficits in
processing speed, and microglial activation in white matter tracts were increased in
F344Tg rats with modest further perturbations driven by ET-1 injury. Persistent
inflammation at the infarct site was observed to exist in ET-1 injured rats. The observed
combined effects of APP and subcortical injury may shed light on the interactions
between AD and ischemic stroke pathology observed in susceptible elderly populations
by exposing possible interactions between white matter fibre tract integrity, subcortical
stroke, and behavioural changes. Future studies will aim to better understand these
mechanisms of interaction with the aim of therapeutic intervention to prevent post-stroke
cognitive impairment in humans.
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Section 1: INTRODUCTION

1

1.1 Alzheimer’s disease & stroke interaction hypothesis
While Alzheimer’s disease (AD) and cerebrovascular pathology are both
characteristic in aging and often coexist 1, numerous clinical studies have identified the
role of cerebrovascular pathology including stroke to contribute to AD pathogenesis and
related cognitive decline

2–4

. Is it estimated that while one in five patients will end up

demented shortly after stroke, one third of patients will become demented following
recurrent stroke 5. In addition, over one third of individuals with AD will show vascular
lesions at autopsy 6. Specifically, Snowdon’s 1997 Nun study identified that in a cohort of
individuals of homogenous lifestyles with a pathological diagnosis of AD, while 57%
experienced cognitive impairments in life, 75% of those with evidence of cortical infarcts
experienced cognitive difficulties, in contrast to 93% of those with evidence of a
subcortical infarct who experienced cognitive issues 4. Overall, the interactions between
subcortical stroke, AD pathology, and incident cognitive impairment is of great interest.
1.2 Dementia and Alzheimer’s disease
1.2.1 Dementia
Dementia is defined as a significant and accelerated loss of cognitive functioning,
typically characterized by impairments in memory, language, attention, judgement, and
problem solving 7. Individuals with dementia place a heavy burden on health services and
place extensive psychological, economic, and practical strain on families of those affected
8

. Global statistics estimate that the number of individuals suffering from dementia will

double every 20 years, expected to impact 42.3 million individuals globally by 2020 8.
AD is the most common form of dementia afflicting the elderly population 9, making up
approximately 60-80% of dementia cases in developed countries
dementia (VaD) at 20%

11

10

followed by vascular

. Statistically, less typical forms of reported dementia include

mixed and Lewy-body type dementias 11.
1.2.2 AD and society
The number of individuals affected by AD worldwide is estimated to be 36 million, a
figure predicted to double by the year 2030

2

12

. We are currently living in an

unprecedented aging society in which AD is placing immense demand on healthcare
systems worldwide, reinforcing a significant need for research into the causes of AD.
There are currently limited efficacious treatment options and no cure for AD

10

. While

much progress has been made in understanding the molecular basis of AD, little success
has been translated to benefit patients as the extensive damage from pathological changes
associated with AD far precede the behavioural changes that patients first experience and
seek help for 13.
1.2.3 AD clinical presentation
AD is a neurodegenerative disease characterized clinically by the development of
memory impairments, a slow progression of general cognitive decline, and an eventual
loss of independence and ability to care for oneself 9,14,15. Typical clinical presentations of
the disease include but are not limited to; loss of declarative short-term memory,
confusion, mood changes, impairments in executive functions such as problem solving,
language disturbances, and overall cognitive deterioration 10.
Clinical presentations of AD occur in either hereditary or sporadic forms 16. The less
common hereditary or familial Alzheimer’s disease (FAD) form occurs due to gene
mutations and products responsible for the processing of the amyloid precursor protein
(APP), including presenilin-1 (PS-1) and presenilin-2 (PS-2), and mutations in the APP
gene itself 16–19. FAD typically presents itself earlier than age 65, often as early as age 30
10

. Conversely, sporadic Alzheimer’s disease (SAD) is age related and the most

commonly observed form with symptoms typically presenting after age 65 12. Numerous
risk factors for development of sporadic AD have been proposed including environmental
and nutritional influences

18

. Currently, a number of susceptibility genes have been

identified including alleles for Apolipoprotein E (ApoE), producing a lipid carrier protein
in the blood

16

and mutations of ‘triggering receptor expressed on myeloid cells 2’

(TREM2), a phagocytic receptor of microglial cells 19. Among the accumulation of other
environmental insults throughout life including incidence of traumatic brain injury (TBI)
20

, the failure of pathogenic protein clearance from the brain, including amyloid-beta

(Aβ), are thought to contribute to sporadic AD pathology 21,22.

3

1.2.4 AD pathophysiology
Clinical observations have identified numerous macroscopic trademark features of
AD to include the global loss of brain gray matter, termed cortical thinning, in addition to
enlargement of the ventricular system, the deep brain cavities that produce and contain
cerebrospinal fluid (CSF)

23,24

. Specifically, thinning of brain regions integral to short-

term episodic memory, including the hippocampus and entorhinal cortex

24

serve as

susceptible early sites of degeneration in the early stages of AD pathology, characterizing
the typical clinical presentation of gradual memory deficits experienced by patients 23. As
AD advances, progressive neurodegeneration in numerous other key brain regions leads
to overall cognitive deterioration and eventual death, a process typically occurring over a
decade 25.
Numerous microscopic events precede these profound macroscopic changes, leading
to the eventual process of neurodegeneration and subsequent cognitive impairment

26

.

Trademark presentations in AD include the accumulation of toxic protein aggregates
including Aβ containing plaques and aberrantly phosphorylated tau

27

, a microtubule-

associated protein that forms aggregated structures called neurofibrillary tangles (NFT) 26.
An overall loss of synapses, neuronal injury and loss, as well as Aβ accumulation in the
microvasculature, termed cerebral amyloid angiopathy (CAA), are typically observed 27,28.
While it is clear both NFT’s and Aβ peptide aggregation contribute to the overall
pathology in AD, the origin of these microscopic changes in AD are often debated
Evidence of the causal role of Aβ in AD progression is numerous

17,28

28

.

, and the focus of

this study resides on the role of Aβ and APP in disease and dysfunction.
1.2.5 The Amyloid Cascade Hypothesis
The current prevailing hypothesis of AD points to the aberrant accumulation of Aβ, a
product of enzymatic processing of APP to be the causative factor in downstream
neurodegeneration and cognitive disturbances as seen in AD

18,29,30

. APP is a

transmembrane protein ubiquitously expressed in most mammalian cells, both neuronal
and non-neuronal
dendrites

7

9,15

. APP is abundantly expressed in neuronal soma, axons, and

and is associated with a complex of transmembrane proteins include β-

secretase and γ-secretase, two key enzymatic components involved in APP processing 26.

4

APP has been shown to act as a cell surface receptor, in cell adhesion interactions, and in
regulating cell division and synapse formation in everyday functioning

18

. Constitutive

enzymatic processing of APP occurs in both non-pathological and pathological conditions,
highlighting the non-amyloidogenic and amyloidogenic pathways, respectively

18

.

Enzymatic processing of APP by β-secretase and γ-secretase result in production of either
a 42 or 40 amino acid sequence protein monomer, the latter making up approximately 90%
of all Aβ produced

18

, while Aβ42 has been shown to be more toxic

18

. While Aβ is

constitutively produced in the healthy brain, it is posited that either an enhanced
production or a reduced clearance of Aβ occurs in AD 31. Upon cleavage from APP, Aβ
may adopt numerous conformations in the extracellular space in the form of monomers,
oligomers, fibrils, and plaques 18.
Aβ senile plaques are dense fibrillar aggregates found in the extracellular space
shown to be toxic to neurons and act to permeabilize nearby vessels

32

18

,

. Aβ plaques

interrupt synaptic signaling in the brain leading to synaptic dysfunction, in addition to
promoting neurotransmitter deficits and axonal damage

7

. Mass cellular death

progressively leads to downstream cognitive and behavioural dysfunction

28

. The

influence of Aβ protein aggregation in AD is of great importance. While Aβ senile
plaques have typically been suspected as the culprit in AD, the inconsistency of
correlation between the presence of Aβ plaques and cognitive problems has hinted
towards the upstream Aβ soluble components and oligomers to in fact precipitate AD
pathogenesis

18

. While countless studies have identified detrimental roles of each

component of the Aβ aggregation process, including monomeric, oligomeric, and plaque
forms

33–35

, further studies must be performed to further our understanding of this

complex pathway.
It should be noted that while Aβ toxic fragments are produced from the constitutive
processing of APP, numerous other proteolytic fragments of APP are constitutively
produced, some of which having demonstrated neuroprotective properties

18

. While the

consensus as to the role of APP in neurotoxicity or neuroprotection is debated, significant
support for the detrimental effects of over-expressed APP come from clinical studies of
Trisomy 21, also called Down’s Syndrome. Over-expression of APP is evident in
Trisomy 21 due to the presence of its gene on chromosome 21. Early-onset AD is

5

observed characteristically in Trisomy 21, indicating a possible role for APP in resultant
AD pathology 36. Additionally, human genetic mutations observed in genes for APP, PS-1
and PS-2, known mutations causing accumulations of Aβ, are known to drive early-onset
AD in humans 28.
Following processing from APP by its enzymatic components, soluble components
of Aβ have a number of possible fates. Proteolytic degradation by neprilysin and insulin
degrading enzyme
circulation
drainage

22

38

37

, efflux across the blood brain barrier (BBB) to be cleared into the

, clearance through the perivascular glymphatic pathway into perivascular

and uptake by microglial and inflammatory cells

39

all serve vital roles in

toxin clearance. If left un-cleared, soluble Aβ has the propensity to deposit into
oligomeric and eventual senile plaque forms, as well as deposition into blood vessels as
CAA 1.
1.2.6 Inflammation
It has become evident that inflammatory responses play an integral role in
neurodegenerative conditions 40. Key players in the neuroinflammatory response involve
activation of microglia and astrocytes 5. Resident microglia contribute to the early host
defense system 41 while acting to repair and prune synapses 42. In the face of injury, these
microglia will respond to environmental cues and act to phagocytose debris to alleviate
toxicity in the environment

41

. This activation transition confers morphological changes

from resting to ramified to amoeboid shaped 41. While activated and recruited microglia
and macrophages have a clear role of clearing debris following injury, numerous studies
have identified secondary deleterious roles of activated immune cells in promoting
cellular damage through pro-inflammatory cytokine release 43.
Microglia are plastic cells capable of taking on varying phenotypes, including M1
and M2 phenotypes

44

. M1 subtype microglia display reduced phagocytosis with

enhanced pro-inflammatory mediator release

43,44

. In response to noxious stimuli, pro-

inflammatory mediators including tumour necrosis factor alpha (TNFα), interleukin-1
beta (IL-1β), matrix metalloproteinases (MMPs), reactive oxygen species (ROS), and
nitric oxide (NO) are released 41,43. While ROS and NO are powerful cytotoxic agents and
promote further inflammatory mediator release, MMPs act to disrupt BBB function,

6

worsening injury by promoting further immune cell infiltration, while chemokine and
cytokine release from activated microglia including TNFα promote cytotoxicity and
further BBB disruption 41. In contrast to M1, M2 subtype microglia are characteristically
phagocytic in nature and exhibit less inflammatory mediator induced damage

43,44

. M2

microglia actively perform phagocytosis of toxic debris and release anti-inflammatory
compounds including transforming growth factor beta-1 (TGFβ-1) and act in promoting
plasticity and neurogenesis through release of other neurotrophic factors 41.
Alterations in another populous cell of the central nervous system (CNS), the
astrocyte, plays an important role in the inherent CNS response to injury. Astrocytes play
integral functions maintaining the BBB and regulating blood flow
myelination and maintenance of homeostatic balance

45,46

45

,

influencing

, as well as in the pruning and

production of neuronal synapses 47. Astrocytes play an important role at the level of the
synapse through rapid clearance of neurotransmitters such as glutamate, enabling
effective axonal conductance and preventing neurotransmitter induced excitotoxicity 45,48.
Astrocytes react by becoming activated following an insult, a process called astrogliosis
49

. Activation can occur by inflammatory mediators including TNFα, interferon gamma

(IFNγ), IL-6, as well as ROS and NO, or toxic buildup of proteins including Aβ 49. These
diverse glial cells are capable of selectively responding to CNS stimuli through the
release of pro-inflammatory or anti-inflammatory mediators dependent on context 49. The
expression of glial fibrillary acidic protein (GFAP) by astrocytes indicates a response of
astrogliosis 50.
1.2.7 Inflammation in AD
In AD, inflammation is triggered in response to local stimuli including Aβ plaque
deposition and NFT formation

39

. Experimental studies have observed the presence of

activated microglia in conjunction with inflammatory mediators including IL-1β and IL-6
at sites of Aβ plaque deposition

39,51

. Chemokine release to promote chemotaxis of

inflammatory cells to noxious stimuli such as Aβ deposits is also observed

52

. Clinical

observations identify cytokines including IL-6, TNFα, acute phase proteins, and
complement proteins tightly associated with Aβ plaques in AD brains 51. The integral role
of microglia as mediators of Aβ plaque clearance is evidenced by experimental APP

7

mouse studies in which impairment of microglial accumulation at sites of plaque burden
markedly increases AD pathogenesis and mouse mortality

53

. However, the presence of

activated microglia may serve deleterious roles in which inflammatory mediators
produced secondarily act to induce neurotoxicity and subsequent neurodegeneration

39,54

,

a problem if microglia remain chronically activated. Increased GFAP and inducible nitric
oxide synthase (iNOS) isoforms in astrocytes are observed to localize around Aβ plaques
51,55,56

, while rodent models demonstrated astrogliosis in response to Aβ injury

57

.

Experimental studies by Leon and colleagues identified major histocompatibility complex
class II (MHC class II) positive signal, indicating M1 microglia, surrounding dense
fibrillar plaques in a Tg-APP model, indicating an effort of activated microglia to remove
toxin buildup 31. Observed increases in reactive astrocytes and microglia are observed in
other Tg-APP models 58.
The role of inflammation in AD is further supported in studies using antiinflammatory administration. Evidenced in arthritic patients who intake daily antiinflammatories

59

and in those with high intake of turmeric, a potent anti-inflammatory

found in spicy dishes

60

, chronic anti-inflammatory therapy may act prophylactically to

reduce chronic low-grade inflammation to prevent development of future AD

52

.

Transgenic APP mouse studies have identified that 6 month long administration of
ibuprofen beginning at 10 months of age, a point at which plaque deposition exists,
reduced overall Aβ deposition with reduced GFAP and IL-1β pro-inflammatory cytokine
presence

61

. Significant findings by Heneka and colleagues

62

identified that in APP-Tg

mice following administration of ibuprofen and pioglitazone, an agonist of ‘peroxisome
proliferator-activated receptor gamma’ (PPARγ) that exhibits anti-inflammatory
properties, reductions in pro-inflammatory cyclooxygenase-2 (COX2) and iNOS,
decreased β-secretase mRNA and protein levels, and decreased Aβ42 deposition was
observed

62

, validating a strong role for inflammation in amyloidogenesis. However,

careful studies must be performed to better understand ideal points of anti-inflammatory
prevention as to prevent inhibition of beneficial inflammatory actions.
1.2.8 Modelling AD in rodents

8

A common goal of AD studies utilizing transgenic and non-transgenic rodent models
is to recapitulate pathological features observed in human AD

58

. Transgenic rat models

utilizing combinatorial mutant APP and PS-1 (APPswe/PS1dE9) display age-dependent
accumulation of AD pathology, characteristic of Aβ, NFT’s, gliosis and neuronal loss in
association with spatial learning deficits 58. Another successful transgenic rat model, the
McGill-R-Thy1-APP model, expressing both Swedish and Indiana mutations of APP,
display extracellular Aβ plaques, glial activation and correlated spatial learning and
memory deficits prominent at age 13 months 31. Other mouse and rat transgenic models of
AD utilize mutations in APP and its associated PS-1/2 components, known human
mutations in inherited forms of AD

18

. The aforementioned studies have played integral

roles in furthering our understanding of AD pathogenesis. An APP rat model developed
in 2008 by Agca and colleagues has further advanced the capabilities for study of AD
pathology in experimental studies

63

. The APP21 Transgenic rat (F344Tg) is a novel

genetically engineered rat model containing human APP with Swedish and Indiana
mutations

63,64

. This transgenic rat model (F344Tg) was developed within the inbred

Fischer 344 rat strain and does not exhibit spontaneous Aβ deposition in brain tissues 63,64.
Rather, the F344Tg is thought to require external challenges to promote pathological
deposition of Aβ. In the APP21, nine months after exogenous seeding of aggregated Aβ
from AD brain extracts, rats developed senile Aβ plaques and cerebral Aβ deposition 64.
Additionally, Silverberg and colleagues induced hydrocephalus in the APP21 rat,
resulting in enhanced Aβ deposition due to blockage of CSF clearance 65. It is evident that
when challenged with external influences, the F344Tg rat recovers more poorly than if
either APP mutations or the external factor were presented alone. We believe that an
external trigger such as ischemic stroke damage may be required to display Aβ related
pathology.
1.3 Stroke
1.3.1 Stroke and society
In industrialized countries, stroke is the most common cause of morbidity and the
second most frequent cause of mortality 66. Given the increased awareness of stroke risk

9

factors and prevention in North America, the total number of strokes has declined over
the decade

67

, though the worldwide impact of stroke continues to pose a significant

socioeconomic and healthcare burden.
1.3.2 Stroke types
Stroke injuries can be broken down into two general types. Hemorrhagic strokes, the
rupturing of a blood vessel leading to a brain bleed, frequently results from hypertension
or from buildup of CAA 68. A second type, ischemic stroke, occurs due to the occlusion
of a blood vessel, frequently caused by atherosclerosis or a foreign or resident blood clot
69

. Ischemic stroke may occur when a clot is formed at a distant site, is dislodged, and

travels to lodge itself in a cerebral vessel; this is termed an embolic stroke and is observed
in cardioembolism 70. The local accumulation of clot material at the site of a blockage is
termed a thrombotic stroke

70

. These classes typically result in larger ischemic infarcts

including the occlusion of large conduit feeding arteries such as the middle cerebral artery
70

. A third classification of ischemic stroke involves the occlusion of small penetrating

blood vessels in deep brain structures or end-arterioles, termed lacunar infarcts

70

.

According to the 2013 Stroke Association Statistics, of all stroke injuries, approximately
87% are ischemic, while 13% are hemorrhagic in nature 71. Of the ischemic strokes, 20%
are considered embolic, 50% are thrombotic, while 25% are lacunar in origin

72

. Of

particular interest to this study is that of subcortical lacunar strokes due to the their
relationship with cognitive impairments 4.
1.3.3 Ischemic stroke pathophysiology
The brain is highly vulnerable to challenges caused by a loss of blood perfusion, as
observed in ischemic stroke

70,73

. Reductions in blood flow cause deprived oxygen

delivery (hypoxia), a loss of met metabolic demands including the delivery of glucose and
vital nutrients, as well as the prevention of waste removal from the deprived site

70,73

.

Hypoxia induced cellular mechanisms including excitotoxicity, ionic hemostasis
disruptions, oxidative stress, edema, and neuroinflammation among others 74,75. Perfusion
reductions lead to numerous changes including adenosine triphosphate (ATP) reductions
causing ionic gradient disruption characterized by Na+ influx and K+ efflux, causing

10

depolarizations of cell membranes

39

. Dysregulation in Ca2+ ionic flow results in

glutamate release, enforcing wide spread effects of Ca2+ dysregulation through
interactions with NMDA and APMA receptors, furthering ionic disruptions and leading to
cellular edema

76

. Further, induced mitochondrial dysfunction causes release of free

radicals contributing to damage of proteins, DNA, and inflammatory cytokine production
39

. The end result of the ischemic cascade results in cellular degeneration 39. In addition,

the evolution of edema in the surrounding spaces further acts to act on vessels and veins
by compressive forces

77

creating more extensive hypoperfusion and possibly increasing

infarct growth 78.
Within minutes after occlusion, cellular death of core and surrounding neural tissue
will occur

39

. The ischemic core is a region of tissue following stroke with highly

restricted blood flow, typically reduced to 10% basal levels

39

neurons and glia alike will die and likely become necrotic

39

. It is in this area that

. A salvageable region

surrounds the core, known as the ischemic penumbra, where cells will experience hypoxia
with 20-60% basal blood perfusion

39

. Current stroke interventions aim to salvage this

sensitive area from loss, with the goal of returning sufficient blood flow in time to prevent
infarct expansion

39

. Intravenous administration of recombinant tissue plasminogen

activator (rtPA), a technique designed to dissolve lodged intraluminal clots, is the only
viable treatment in the acute phases of ischemic stroke, typically administered within 4.5
hours of injury

79

with the goal of restoring blood flow and function to ischemic brain

regions. Prophylactic use of anticoagulants is a viable preventative strategy 76.
1.3.4 Inflammation in stroke
As in AD, inflammation plays an integral role in the post-ischemic cascade that
acts on influencing the extent of tissue damage and repair following ischemia

80

. The

inflammatory response following ischemia involves a complex combination of actions
from both resident inflammatory cells, including resident microglia and astrocytes, as
well as the recruitment of blood-borne inflammatory cells; a process that takes 3-7 days to
develop 80. Ischemic neurons and other cells release mediators including ATP and ‘high
mobility group box 1 protein’ (HMGB1) that signal to activate microglia at the injury site
81

. Further, hypoxia and nutrient loss during ischemia will signal to activate microglia and

11

astrocytes 39. Activated microglia will also act to produce MMPs which act to impair the
integrity of the BBB and neurovascular unit, promoting leukocyte infiltration into brain
parenchyma

46,82,83

. Resident and peripherally translocated microglia release pro-

inflammatory cytokines including IL-1β, TNFα, IFNγ, and attractant chemokines
further promote immune cells to the injury site

43

81,84

to

. Microglial and astrocytic release of

ROS, inflammatory cytokines and MMP’s from activated microglia play a role in
promotion of bystander damage

85

causing secondarily damaging effects in the ischemic

region including free radical formation, excitotoxicity and further ischemia

41

. Affected

glia will release inflammatory cytokines, often acting on themselves to exacerbate glial
responses 76. Additionally, a number of pro-inflammatory pathways are initiated in stroke
76

. Gene activation of kinase-cascade molecules including c-Jun NH2-terminal kinase

(JNK) and p38 mitogen activated protein kinases (MAPK) are observed to respond with
inflammatory cytokine release following ischemia, and are responsible for the production
of mediators including IL-1β and TNFα, iNOS, and IL-8 chemokines

39

. During acute

recovery, astrocytic contributions include lesion encapsulation by a glial scar, a structure
composed of activated microglia and astrocytes that acts to both contain and resolve the
lesion 85. Further, astrocytes may contribute to inflammatory effects through secretion of
pro-inflammatory cytokines 45. Peripherally, inflammatory results include increases in Creactive protein (CRP), MMP-9, and IL-6

46

. Anti-inflammatory intervention has also

proven successful in experimental models of stroke

39

. Further, inhibition of the p38-

MAPK pathway is shown to reduce ischemia severity in global ischemia models

86

,

evidence of the role of inflammation in infarct growth.
1.3.5 Modelling ischemic stroke
In modeling stroke and cerebrovascular disease, rat models are important due to the
similarities to a human in terms of cranial circulation 87. Thorough reviews with extensive
coverage of available experimental stroke models and parameters aid in choosing the best
stroke model to answer experimental questions in stroke research

70,88,89

. The choice of

stroke model must be reflective of the clinical research questions to be investigated, given
that human ischemic strokes vary drastically dependent on their cause, location and size
74,75

.
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A common technique to model severe ischemic injury of the cortex and sub-cortices
of the brain is the Middle Cerebral Artery occlusion (MCAo) model, a reproducible
model that gives consistent histological consequences

90,91

. The filamentous model of

MCAo involves insertion of an endovascular monofilament into the rat cerebral
vasculature to induce blockage at the site of the origin of the MCA, effectively depriving
the MCA feeding regions of blood, leading to rapid ischemia

92

. Ischemia is induced

either transiently or permanently dependent upon the duration of time the monofilament is
blocking the MCA origin

92

. However, MCAo induces severe ischemic injuries that are

often accompanied by high mortality rates

93

. In particular, severe ischemia is not well

tolerated by certain rat strains such as the F344 strain

94–96

, further increasing rates of

mortality following surgery and throughout the recovery process. Other methods of
MCAo involve the injection of microspheres selective for MCA blockage
MCA coagulation methods through a cranial window

87

97,83

, direct

, intravenous administration of

thrombin-rich emboli 79 and photothrombotic stroke models 98.
While MCAo induces a large ischemic injury, a more focal, less severe method of
ischemia may be induced using endothelin-1 (ET-1), a potent vasoconstrictor

99

. This

chemical compound exerts receptor-mediated signaling effects upon binding to
endothelin receptors of endothelial cells on blood vessels, effectively inducing
vasoconstriction 70. Studies show that based on regional cerebral blood flow (rCBF) using
MRI perfusion tools, an acute reduction in blood flow at the 1 h post-injection time point
occurs with blood flow returning back to normal by 3 h

100

. Any vessel containing

receptors in contact with ET-1 will constrict, effectively preventing blood flow from
reaching the affected regions, causing ischemia induced hypoxia, loss of met metabolic
demands, and the aforementioned ischemic cascade

70

. ET-1 induced ischemia is

advantageous in that it provides a highly reproducible injury, offering mild ischemic
damage

101

. ET-1 induced ischemia is flexible in that the location of injection may be

modified to suit the needs and research questions of the experimenter, while ischemic size
may be modified by altering the concentration and volume of ET-1 injected, a dosedependent effect 102. Pitfalls associated with ET-1 induced ischemia includes the need for
drilling a burr hole, perforation of the BBB due to its injectable nature, secondary damage
caused by the needle, as well as non-specific effects of ET-1 acting on non-desirable
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receptors including the ETB receptor of neurons and astrocytes

70,100

. Endothelin-1 has

been utilized in numerous experiments including studies of injury and recovery of
cognition and motor impairment
subcortical lacunar injuries

57,85

57,103,104

, and has been used experimentally to model

. In our study, the use of ET-1 in modelling subcortical

lacunar stroke is aligned with Snowdon’s observations relating lacunar infarcts to
cognitive impairments in the Nun Study 4.
1.4 White matter
1.4.1 White matter health and injury
In the brain, white matter fibre tracts are composed of bundles of axons that serve
to connect and enable communication between areas of gray matter 105,106. These bundles
are covered in myelin, a compound that provides electrical insulation to fibre tracts,
giving a white appearance

106

. White matter health is integral for action potential

conductance and transport of biological molecules from somatic to synaptic regions
Damage to these connections may perturb neuronal transmission
cognitive, motor, and sensory disruptions

105

85

46

.

and may result in

due to the vital importance of white matter

integrity in proper cellular communications and cognitive functions

107,108

. Damage to

axonal tracts, termed axonopathy, is characterized by perturbations in axonal transport as
well as swelling and varicosities in axonal processes 109, a characteristic feature observed
in AD and rodent models of AD

20,110,111

and in axonal damage from stroke

109

. In post-

mortem samples and following injury, the presence or accumulation of APP is a reliable
indicator of axonal injury
axonal transport

114

100,112,113

. In white matter, APP is transported through fast

, while interruption of axonal transport has been shown to enhance

processing of APP, giving rise to increased Aβ deposition and plaque development

20,110

.

Experimental stroke studies have identified increased APP localized around the infarct
periphery 113, an acute response that is shown to decrease after 24 h post-injury 100.
While much focus rests on the role of ischemia on gray matter, it has been estimated
that 30% of strokes affect subcortical white matter 115. White matter and oligodendrocytes
display a uniquely high susceptibility to injury and ischemia due to its limited blood
supply

46

, with enhanced vulnerability to inflammatory mediators

14

41,85

, oxidative stress

and excitotoxicity associated with ischemia 46. Ischemia in white matter is characterized
preferentially by demyelination, damage to axons, oligodendrocyte death and edema, a
cascade heavily involving activation of astrocytes and microglia
ischemia is characterized by excessive glutamate release from axons
of homeostatic ionic balance

107

115
48

. White matter

due to a collapse

. Excess glutamate acts on AMPA and kainite receptors

resulting in Ca2+ dys-homeostasis and excitotoxicity induced death of oligodendrocytes,
axonal damage, demyelination, and possible downstream behavioural alterations

46,48,105

.

These events are also promoted by ischemia induced inflammation following infiltration
of microglia into the white matter during the acute ischemic response 85 while free radical
production and oxidative stress further damages white matter components 46,107.
1.4.2 Clinical associations in white matter injury
White matter injury, also referred to as leukoaraiosis, is evident in greater than half
of the healthy elderly 116, while the presence of white matter injury is thought to increase
risk of stroke and post-stroke dementia 117. In aging, white matter in rodents and humans
displays an enhanced susceptibility to ischemia

107

whereby the presence of fewer

oligodendrocytes with age may result in more severe injury after white matter ischemia
118

. Clinical investigations have identified relationships between stroke injury to white

matter circuitry and behavioural and cognitive changes, often manifested by altered
behavioural outcomes including cognitive and sensorimotor impairments, as well as
emotional manifestations

46

. Specific interests lie in the relationship between lacunar

infarcts, their involvement of white matter, and the unique behavioural impairments
observed following these injuries. Typically affecting vessels including the deep
penetrating lenticulostriate arteries that provide support to subcortical structures such as
the basal ganglia, lacunar infarcts are estimated to account for roughly 20-25% of all
strokes in humans 85,115,119. Often referred to as “silent strokes,” lacunar infarcts are found
in 33% of healthy adults of middle age without their knowing

120

. These silent ischemic

events are thought to occur five times more frequently than large disabling strokes

121

.

While lacunar infarcts are infrequently disabling, they are implicated in progression to
vascular cognitive impairment and are characteristic of cerebral small vessel disease
(cSVD), implicating issues with executive function and attention 122. In cSVD, damage to

15

white matter is a defining hallmark

119

, while the relationship between executive

dysfunction and processing speed deficiencies to lacunar stroke and poor white matter
integrity has been frequently reported 123,124.
1.4.3 Behavioural implications and subcortical white matter injury
Damage to white matter fibre bundles on a global scale in both humans and rodents
would be expected to contribute to deficits in wide arrays of cognitive and sensorimotor
outcomes as observed following stroke

113

. In the rat, tasks including novel object

recognition (NOR), open field (OF) and strategy set-shifting are heavily reliant upon
integration of neural networks that connect distant nuclei

125,126

and may be powerful

measures for assessment of white matter health in rats. NOR in rodents is a task reliant
upon subcortical to cortical circuitry including the medial prefrontal cortex (mPFC),
hippocampus, and medial dorsal thalamus (MDT) 126, while strategy set-shifting is reliant
upon circuitry of the mPFC, nucleus accumbens (NAc), and MDT

125

. Behaviours

assessed in OF analysis rely on circuitry connecting the basolateral amygdaloid nucleus
(BLA), ventral hippocampus, and lateral entorhinal cortex 127.
1.4.4 Rodent models of white matter injury
Specific rodent stroke models are utilized to preferentially affect white matter, or aim
to affect both white and gray matter. Endothelin-1 57,85,128, gradual hypoperfusion models
129

, and endovascular microsphere injection

130

provide novel models of inducing white

matter injury. Hattori and colleagues model of gradual hypoperfusion from common
carotid artery (CCA) gradual constriction produces scattered subcortical infarcts and
white matter pathology, common characteristics observed in clinical vascular cognitive
impairment (VCI) 129.
1.5 Executive functions
1.5.1 Executive function and dysfunction in humans
Executive functions are higher order cognitive skills including; attentional control,
cognitive flexibility, and working memory

131

16

. The ability to multitask, solve complex

problems and plan are essential skills to human survival and adaptation in the face of
challenges 132. A specific domain of executive function, known as behavioural flexibility,
is defined as the ability to adapt behaviour to altered environmental stimuli 133. Executive
functions are highly dependent on specific regions of the prefrontal cortex (PFC) and its
extensive associations with limbic structures including the NAc and hippocampus, as well
as with basal ganglia structures, thalamus, and hypothalamus

134,135,136

. Clinically,

executive dysfunction, an impairment in executive functions, often occurs with patterns
of disease and degeneration that affect changes in the PFC
dysfunction is observed to occur with natural aging
early symptom of AD
135,138,141

139,140

137

134

, whereby executive

, following stroke

138

, and as an

. Executive dysfunction is a common complaint in VaD

and often arises in patients suffering from silent lacunar strokes in subcortical

structures 121, a process hypothesized to be mediated by damage to adjacent white matter
bundles in the subcortical regions that project to frontal cortex based structures. This
white matter pathology, termed leukoaraiosis, is a pathological feature speculated to be
heavily influenced by subcortical ischemia and in driving the process of dementia 142. The
incidence of subcortical stroke has been correlated with poorer performance on tests of
behavioural flexibility including the Wisconsin card sorting task (WCST) in humans

143

.

As executive dysfunction has been observed in patients who have suffered stroke, AD, or
both

140,144,145

, the development of behavioural testing and adaptation of executive

function based testing in rodent models of AD and stroke is a critical addition in
understanding the contributing roles of disease states to pre-clinical rodent models.
1.5.2 Executive function and behavioural flexibility in rodents
As discussed, behavioural flexibility is a critical component of executive functioning
and is frequently tested in rodent studies

146

. In the rat, behavioural flexibility has been

shown to be mediated by intricately connected cortical-subcortical association circuits
composed of the mPFC, NAc core and shell, and MDT, each mediating defined roles in
the process

147

(Fig. 1). In rats, forms of behavioural flexibility including strategy set-

shifting and reversal learning test an animal’s ability to disengage from a previously
rewarding strategy and adopt a novel strategy that was previously unrewarding 148. In the
case of strategy set shifting, an extradimensional shift tests the animal’s ability to shift
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Figure 1: Neural circuitry involved in rodent behavioural flexibility. Regions of the
prefrontal cortex (PFC), nucleus accumbens (NAc) core and shell, and medial dorsal
thalamus (MDT) play integral specialized roles in the complexity of behavioural
flexibility. Figure modified from Floresco et al. (2009) 148.
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attention from one sensory dimension to another

148,149

for example, shifting attention

from a visual strategy to a direction based strategy 148. A number of different methods of
testing behavioural flexibility in rodents may be utilized. Set-shifting tasks utilizing odor
and texture discrimination, cross-maze discrimination tasks, and a more recent automated
task utilizing an operant chamber approach have been utilized 131,150,151. The current study
utilized a novel operant based approach to test behavioural flexibility in the rat, a task
analogous to the WCST used in human studies 27,152.
1.5.3 Behavioural flexibility error types and implications
As mentioned, the underlying concept of testing behavioural flexibility with setshifting in the rodent involves the ability of a rat to effectively shift attention from a
relevant stimulus to a separate stimulus of different stimulus dimension

151,153

. The

degree of flexibility in a rat’s strategy shift appears to be reflective of the integrity of the
neural circuitry that mediate these functions, as observed in experimental testing

150

. For

example, excitotoxicity or ET-1 induced mPFC lesion studies in rats reveal selective
impairments in the ability to disengage from a previously rewarding response strategy, a
phenomenon characteristic of perseveration

125,153,154

. ET-1 induced stroke lesions to the

MDT are also expected to cause this perseverative phenotype

153

. Neural connections

from the mPFC to NAc are responsible for the maintenance of a new strategy (Fig. 1) as
observed in inactivation and lesion studies of NAc characterized by selective impairments
in novel strategy maintenance reflected in increased numbers of regressive errors

148,155

.

In addition, the NAc core appears to play a vital role in disregarding irrelevant response
options that are not predictive of food reward, as evidenced by increased numbers of
never-reinforced errors in NAc core inactivation studies 148.
Overall, executive function based behavioural flexibility testing has significant value
in

investigating

declining

cognitive

states

in

disease-accelerated

aging

and

neurodegenerative disease research. Considering the evidence suggesting a role for
executive dysfunction in AD and stroke

138,139,140

, developing a pre-clinical model of

executive function in rodent studies of AD/stroke could prove invaluable for therapeutic
intervention studies in post-stroke cognitive decline.
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1.6 AD and stroke interaction
1.6.1 Possible mechanisms of interaction between AD and stroke
As discussed, the relationships between subcortical stroke, AD pathology, and
cognitive impairment is of key interest. The progression of both AD and stroke is reliant
upon the interactions between hereditary and environmental factors alike 6. The most
predominant, non-modifiable risk factor for both stroke and AD incidence and
progression is age 156,84. Other shared risk factors include hypertension 157, atherosclerosis
158

, and atrial fibrillation

159

, while both conditions share clinical presentations including

cognitive and functional deterioration 6. Stroke and AD share common pathological
mechanisms including neuroinflammation, perturbed clearance of toxins, and oxidative
stress

39,160

. Individually, these mechanisms play integral pathological roles in both AD

and stroke, while a possible pathological synergism may exist when presented together.
A schematic developed by Thiel and colleagues in our lab presents the clinical
comparison of four patients to shed light on the proposed interaction between AD and
stroke pathologies (Fig. 2) 5. Referring to Figure 2 5, type A highlights a patient who
experiences a stroke but has no presence of AD pathology, while Type D experiences a
stroke in the presence of previous AD pathology. While the incidence of a stroke may
lead to acute injury (Type A), the added influences of AD pathology may worsen
recovery from the stroke injury, causing a gradual decline in cognition (Type D).
Additionally, in the presence of AD pathology including Aβ, the interaction of stroke and
AD pathologies may likely lead to worsened pathology through additional secondary
mechanisms including hypoperfusion, impairments in toxin clearance, oxidative stress, or
recurring stroke, leading to a permanent inflammatory state in the brain (Type C). In a
feed-forward nature, these injuries may act on each other to result in accelerated
pathology and resultant cognitive decline. In our study and past studies from our
laboratory, the combination of AD and stroke influences has been shown to exhibit
pathology characteristic of Type C or D, while the long-term effects of injury
combination, as observed in clinical Type C
models. Our study aims to fill this gap.
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5

has not been investigated in our animal

Figure 2: Potential trajectories of cognitive decline in clinical AD/stroke.
Contributions of amyloid pathology, stroke, inflammation, and other secondary factors
may influence the magnitude of neurodegeneration and downstream cognitive decline in
susceptible populations dependent upon the present factors in individuals. Figure
modified from Thiel et al. (2014) 5.
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1.6.2 Modelling AD and stroke in rodents
Rodent models of comorbid injury have been integral in our understanding of the
pathological interactions between disease states. Numerous experimental studies have
revealed a two-fold interaction in which 1) ischemic stroke can increase Aβ pathology,
and 2) Aβ pathology worsens stroke outcome and the magnitude of injury. In this light,
the presence of cerebrovascular and Aβ pathology may work in a feed-forward fashion,
interacting to worsen pathology and downstream cognition.
1) Ischemic stroke can increase APP/ Aβ pathology at injury site
Numerous studies have identified the role of stroke injury in influencing alterations
in APP translocation and processing with subsequent downstream Aβ production. Studies
have shown that following stroke injury, increased APP

161

, APP enzymatic processing

products 162 and APP mRNA levels 163 were observed in or surrounding the stroke injury,
while selective increases of APP were found in axonal swellings and dystrophic neurites
on the infarct periphery

164

. PS-1 mutated mice have observed increased Aβ production

and related neurodegeneration following ischemia

165

. Axonal injury associated with

cerebral ischemia has been associated with increased levels of β-secretase enzymes at the
injury site

160

, an upregulation that has also been observed following TBI and other

injuries associated with axonal damage

166

. Additionally, stroke has been observed to

increase BBB permeability, resulting in the extravasation of Aβ components from the
bloodstream into the site of injury in the brain parenchyma

167,168

. Increased APP

expression has also been observed in glia following global cerebral ischemia 169. Clinical
studies have identified the role of ischemia in influencing Aβ

170

and APP

164,171,172

accumulation in the ischemic region after mild and severe brain ischemia. Overall, these
experiments identified Aβ and other APP cleavage products at the site of injury leading to
enhanced Aβ pathology.
2) Aβ pathology worsens stroke outcome and downstream events
MCAo ischemia in an APP transgenic mouse model

173

, APPswe/PS1dE9 mouse

model 37 and APdE9 transgenic mouse 174 have observed increased infarct sizes up to one
week compared to WT controls with concomitant reduced CBF in Tg animals 173. Studies
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hypothesize that infarct sizes increase in the presence of Aβ due to the effect of Aβ on the
surrounding vasculature whereby Aβ reduces endothelial cell-dependent vascular
responses, interfering with the ability of endothelial cells of the vasculature to respond to
vasodilatory effects

173,175

. This would act to effectively reduce cerebral blood perfusion,

leading to a state of hypoperfusion 175. Additionally, it is speculated that this effect occurs
while Aβ is in its soluble form prior to evident plaque burden 1. CBF reduction has also
been observed in striatum of Aβ/ET-1 injected rats

176

and in mouse models of APP

overexpression without ischemia, a process reliant upon the hypoperfusive induced state
of Aβ

177

. Larger infarcts have been observed following ischemia both in a APdE9 Tg

mouse model

174

and in models of intracerebroventricular (ICV) injections of Aβ

57,103

,

speculated to be due to enhanced mechanisms of neuroinflammation and cellular and
oxidative stress following the combination of insults 103,160,174. Studies have also identified
Aβ plaque development with subsequent spatial learning deficits with chronic
hypoperfusion induction in an APPswe/PS1 mouse model

178

. The observed

vasoconstrictive effects of soluble Aβ are observed to be inflammatory mediator driven
179

. Clinically, states of hypoperfusion are shown to increase ipsilateral Aβ deposition in

demented patients with unilateral carotid artery stenosis

180

. In general, hypoperfusion as

a result or ischemia, atherosclerosis, or other conditions including carotid insufficiency
may induce neurological deficits and progressive dementia
hypoperfusion is an observed early event in AD

178

32

, while chronic

. Overall, Aβ may induce a state of

hypoperfusion that acts to worsen stroke injury.
Aβ has been shown to act on neurons to influence neurodegeneration
neurotoxicity
168,173

173

168

,

, as well as the generation of ROS in creating progressive oxidative stress

. An enhanced state of oxidative stress has been observed to act on secretase

enzymes

160,181

to further increase APP processing and enhance Aβ production

181

.

Fibrillar Aβ acts on dendrites to produce spine loss and atrophy, leading to neurite
breakage and neuronal disconnection

182

. During cellular stress, APP is shown to be

upregulated in microglia, astrocytes, and in neurons

39,165

while APP is observed to

enhance the oxidative neurotoxic state of the cell by inhibiting bilirubin production, an
antioxidant and neuroprotective compound

183

. Further, Aβ has also been shown to

activate p38-MAPK pathways in vitro, a similarity with stroke pathophysiology, acting to

23

produce inflammatory mediators

184

. Aβ may also accumulate as CAA in blood vessels

leading to reductions in blood flow, causing additional ischemic injuries

1185

. While the

relationship between Aβ induced CAA and incidence of hemorrhagic stroke is clear,
CAA in vessels is also thought to contribute to brain ischemia and resultant cognitive
impairment 1. Aβ deposition in capillaries has been shown to cause capillary occlusion 185
effectively causing hypoperfusion and ischemia in tissue without the presence of stroke,
frequently resulting in small cerebral infarcts

186

. Further, vascular deposits of Aβ in

vessels can lead to inflammation of the vessels

167

. Preston and colleagues further

speculated that the toxic role of Aβ on endothelial cells in the cerebral vasculature may
lead to endothelial cell degradation, causing BBB interruption and leaky vessels

187

.

Overall, the presence of Aβ may further promote a toxic environment conducive to
promotion of inflammatory reactions.
1.6.3 Neuroinflammation – a feed forward cascade
Enhanced Aβ/APP pathology at the site of injury and worsened stroke outcome
are independently observed to stress neuroinflammatory mechanisms to worsen the
overall pathology state through mechanisms of hypoperfusion, oxidative stress, Aβ
accumulation, and inhibited clearance of toxic by-products

55,168,174

. Induced states of

oxidative stress and hypoxia, as individual mechanisms, tend to stimulate release of proinflammatory cytokines upon microglia and astrocyte activation

55

. Pro-inflammatory

cytokines produced in stroke and AD pathologies are observed to stimulate γ-secretase
activity, enhanced APP levels and processing of APP, in turn worsening Aβ pathology
188–190

APP

while an induced state of hypoperfusion is shown to act to increase cleavage of

32

. Endothelial cells are frequent responders to stimuli in both stroke and AD, in

which cluster of differentiation 40 (CD40), IL-1β, and prostaglandins are frequent
mediators released

39

, while the activation of glial cells and subsequent inflammatory

mediator release are cardinal consequences in the development of AD and stroke
pathophysiology 39. Increased BBB permeability due to the presence of Aβ, as observed
in both clinical and experimental studies of AD, plays a role in recruiting leukocytes
across the BBB and into the brain parenchyma

191

, furthering immune cell recruitment

and activation. Combinatorial Aβ/stroke models have observed increased microgliosis in
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the hippocampus

128

and increased expression of activated microglia and activated

astrocytes at the infarct site

57

. Exacerbated neuroinflammation characterized by NFκB,

OX6, and GFAP increases following ET-1 induced striatal infarcts in an APP23-Tg
mouse model have been observed

192

. Overall, inflammatory mediator release due to Aβ

and stroke damage with subsequent activation of inflammatory cells likely makes the
brain tissue more susceptible to ischemia 39.
Anti-inflammatory investigations in the model of ICV Aβ/striatal ET-1 injections
showed proven efficacy in improving the inflammatory state of either injury model alone,
while anti-inflammatory treatment in the combined AD/stroke model could not alleviate
the ensuing inflammation

57

. It is evident that inflammation, characterized by increased

microglial and astrocytic activation, is a hallmark in these processes and may prove to be
overwhelming in the system. While individual neuroinflammatory processes have been
discussed in stroke and AD as individual injury states, real life examples in humans and
experimental rodent studies featuring both disease states may in fact experience severe
feed-forward stimulation of inflammatory processes through perpetual recruitment and
activation of microglia, leading to persistent inflammation as suggested by Thiel and
colleagues (Fig.2) 5. It is anticipated that this worsened pathological state will produce
extensive gray and white pathology leading to worsened cognitive impairments, as
observed in Type C of Thiel’s schematic (Fig.2) 5.

25

1.7 Rationale, Aim and Hypothesis
Clinical evidence suggests that AD and stroke not only co-exist as comorbidities but
also reciprocally interact 2–4. Pre-clinical studies continue to focus on this interaction and
have identified potential points of intersection, namely inflammation

103,193

. Executive

dysfunction is a key clinical manifestation of stroke and likely is an early indicator for
future cognitive impairment associated with AD

139,140,144,145

. Since executive functions

are behaviours heavily dependent on functional white matter connectivity between neural
regions
stroke

131,151

; and changes to white matter are observed in both AD

123,124,119

20,110,111

and lacunar

, identifying mechanisms of white matter degeneration will continue to

play a vital role in our understanding of the pathogenesis of both AD and stroke.
Our lab has shown that inflammatory processes may play a role in white matter
degeneration in pre-clinical models of AD and stroke. Therefore, it is possible that
persistent white matter inflammation could be a key mechanism driving executive
dysfunction and the reciprocal interactions between AD and stroke. To address this, work
in this thesis aimed to test executive function following a subcortical lacunar-type stroke
into an aged transgenic rat (F344Tg) that contains the double human (Swedish/Indiana)
mutations to APP. This rat has elevated levels of white matter inflammation and is
therefore a strategic model to investigate the prodromal phase of AD as well as to
investigate the behavioural underpinnings of stroke-induced changes that could lead to
AD. A single subcortical injection of endothelin-1 will be used to model lacunar stroke in
an effort to accelerate white matter pathology.
Hypothesis: Aged hAPP rats will display executive dysfunction and white matter
inflammation, effects enhanced by a subcortical stroke.
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Section 2: METHODS
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2.1 Animals
Ethics and procedures were approved by the Animal Care Committee at Western
University (Protocol 2014-016). Thirty-seven male Fischer 344 (F344) rats with weights
ranging from 340-450 g, aged 12-13 months, were used in this study. F344 breeding pairs
were generously provided by Agca and colleagues

63

and homozygous wild-type (WT)

and Fischer344 transgenic (F344Tg) rats were further bred and aged in house. Rats were
housed in colony cages at the Western University Animal Care and Veterinary Services
on a 12:12 hour light/dark cycle alternating at 1AM/PM. Behavioural testing occurred
during the animal’s dark cycle.
2.2 Rat models
2.2.1 APP21 transgenic model (F344Tg)
The APP21 rat was used to model an overexpression of pathogenic human APP
(hAPP). APP21 was developed by Agca and colleagues using lentiviral infection and bred
in the Fischer344 (F344) strain. APP21 rats have been shown to demonstrate a 2.9 fold
increase in mutated (Swedish/Indiana mutations) human APP mRNA in neuronal cell
membranes 63. The Swedish mutation of APP significantly increases β-secretase activity,
effectively increasing production of Aβ

194

while the Indiana mutation of APP increased

the ratio of Aβ42/40 195. APP21 rats have been shown to express high levels of Aβ40 and
Aβ42 in serum
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. APP21 rats are a unique APP mutated strain in that rats do not

spontaneously deposit and accumulate Aβ lesions in the brain parencyhma 63 as observed
in various other APP transgenic rat strains 31,58.
2.2.2 Endothelin-1 focal ischemia model
Focal subcortical ischemia was modelled using a single injection of endothelin-1
(ET-1), a potent vasoconstrictor

115

into the striatum. This stroke model was chosen as it

mimics ‘silent’ subcortical strokes seen in humans 115,145 that have been shown to interact
with AD-related pathology to synergistically increase cognitive impairment and brain
deterioration 4. WT and F344Tg rats were randomly selected for either an ET-1 or saline
injection (WT/saline, n=6; WT/ET-1, n=10; F344Tg/saline, n=8; F344Tg/ET-1, n=13).
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Briefly, surgery was conducted under isoflurane anaesthetic (Baxter Corporation,
Missisauga, Canada) (for induction, 4% with 2.0 L/min of oxygen, and shifted to 2%
isoflurane once in surgical plane). Prior to surgery, 0.03 mg/kg buprenorphine diluted in
0.9% sterile sodium chloride (saline) was administered subcutaneously. While under
anaesthetic, rats were placed in a Kopf stereotaxic frame where an incision was made in
the scalp and a single burr hole was drilled (AP: +0.5 mm, ML: -3.0 mm, DV: -5.0 mm
relative to bregma). A single injection of ET-1 (60 pmol dissolved in 3 µl sterile 0.9%
saline over 5 min) was injected unilaterally into the right dorsal striatum (caudateputamen) using a 32-guage Hamilton syringe (Hamilton Company, Reno, NV, USA). Full
saline controls underwent the identical procedure with equivalent time under isoflurane
anaesthetic, pre- and post-operative care. Rats were injected with 0.03 mL of Baytril
(intramuscular, Bayer Inc., Toronto, Canada) post-surgery. Following ET-1/saline
injection, animals were placed in their home cage and allowed to recover and live freely
for 3 months (Fig. 3). Behavioural testing began at 16 months, followed by euthanasia at
17 months of age. A post-ischemia (within 24 hours) mortality rate of 6% with a 24%
mortality rate (WT-13%, F344Tg-11%) over the 4-month duration prior to euthanasia
were observed. Surgical groups and genotypes were balanced in surgery by day to
eliminate confounds introduced on a daily basis.
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Figure 3: Surgical and behavioural timeline. Rats underwent surgery (injection of 60
pmol endothelin-1 (ET-1) in 3 µl saline, or 3 µl saline) at 13 m of age. Rats were allowed
to survive for 3 m, followed by behavioural testing for strategy set-shifting, open field
(OF) and novel object recognition (NOR). Rats were euthanized following behavioural
testing at 16.5-17 m of age (3.5-4 m post-surgery).
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2.3 Behavioural testing
2.3.1 Strategy set-shifting
The visual cue to response discrimination strategy was utilized in this study (Fig. 4).
A detailed description of this strategy set-shifting task is found in Floresco et al. (2008),
while specific strategies and techniques pertaining to the efficient flow of set-shifting
testing is outlined in a later publication

151,196

. Overall, no subjects were omitted as all

were able to reach criteria during testing.
Apparatus
Two operant chambers (Med Associates, VT, USA) were fitted in sound attenuating
chambers. Each box was fitted with two retractable response levers on both sides of a
central food pellet dispenser. A bright stimulus light was located above each lever, and a
house light located at the back of the apparatus at roof level. Each chamber was attached
to a computer running MED-PC (Med Associates, VT, USA) software with customized
codes, allowing automated control of experimental inputs/outputs and recording and
saving data. A portable camera (Grand & Toy, Canada) was mounted on the roof of the
operant chamber to visualize the animal performing the task, allowing for recording and
archiving of videos. The central pellet dispenser delivered a 45 mg banana flavoured
sucrose pellet (Dustless precision pellets, Bio-Serv, NJ, USA) as a food reward
immediately following correct lever responses. Testing was performed at the same time
daily, and animals were only tested in one box for the experiment duration.
Food restriction
Prior to testing, single caged rats were fed ad libitum with free access to water. Prior
to food deprivation, free feeding weights are measured. Food restriction was initiated 6
days before testing, with a target weight of 85% free feeding weight to promote foodrewarding motivation. Animals were weighed periodically over the testing period to
ensure no fluctuations in weight occurred. Water was provided freely throughout the
testing period. For the final 3 days prior to testing, approximately 10 sucrose pellets were
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Figure 4: Strategy set-shifting testing paradigm. Rats were tested on a visual cue
related task until proficient, then forced to shift to an egocentric direction based task
(extra-dimensional shift) to assess the rat’s ability to abandon a previously rewarding
strategy (follow the light) and adopt the previously unrewarding strategy (ignore the light,
follow the direction). Figure modified from Floresco et al. 2011 131.
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placed daily in the rat’s cage to allow for acclimation to the future reward used in testing,
preventing neophobia during testing.
Pre-training
Rats were first habituated to the testing chamber for 20 min, followed by lever
pressing shaping. The experimenter, with manual control of operant chamber inputs, was
able to control lever retraction and extension as well as pellet reward delivery. While
visualizing the animal in the operant chamber, classical operant conditioning strategies 197
were used to initially associate lever pressing with a food reward. Rats were first trained
for 15 lever presses on one lever, followed by 15 lever presses on the opposite lever.
Criteria for lever press shaping was achieved once the animal was able to alternate
between left and right levers 15 times. The animal was placed back in its home cage
following training.
The next day rats were trained in retractable lever training, a fully automated training
task. The session began with both levers retracted in the dark chamber. A trial began once
the house light illuminated and a lever was extended (counterbalanced left to right each
trial), allowing the animal 10 sec to respond on the available lever to receive a food
reward (rewarded on a fixed-ratio, in which a correct lever response was rewarded
immediately with one sucrose pellet). If successful, a single sucrose pellet was delivered
via the food dispenser following the response, and the house light remained lit for 3 sec.
If the animal did not respond on the extended lever within 10 sec, an omission was
recorded, no food reward was given and the house darkened. The session consisted of 90
trials, with a 20 sec inter-trial duration. An animal reached criteria if no more than 5
omissions were made in 90 trial opportunities. Stimulus lights were not utilized in this
training phase.
Side bias determination
Upon meeting training criteria, rats were first presented with both levers, in which a
response on either lever resulted in a food reward. With an inter-trial duration of 20 sec,
both levers were again extended, however only the opposite lever reliably provided a food
reward. This phase consisted of 7 trials, with the side bias determined to be the lever that
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was responded on first in > 60% of the opportunities. Upon completion, the animal was
placed in its home cage to be tested on the visual cue discrimination test (Fig. 4) the
following day.
Visual cue discrimination (VD) testing
Twenty-four h following completion of side bias determination, rats underwent VD
testing, consisting of 100 trials. On each trial, illumination of the house and illumination
of one salient stimulus light preceded the extension of both levers by three seconds. The
rat had to choose between the lever associated with the stimulus light or the opposite
lever with no stimulus light illuminated. The rat had 10 sec to respond on a lever in which
a response on the lever with the corresponding illuminated stimulus light would result in
food reward, followed by the house light staying lit for 3 sec. An incorrect response
resulted in both levers being retracted, no food reward, and the house light going off. If
10 sec passed, the trial was recorded as an omission and no food reward was provided.
The location of the stimulus light was counterbalanced and presented equally over both
levers during the test. Criteria was met when 8 consecutive correct responses were made.
All animals were equally presented with 100 trials in a testing day. If criteria were not
met within the allotted trial limit, the animal was placed in its home cage and re-tested the
next day.
Shift to response discrimination (RD) testing
Twenty-four h after VD criteria was attained, rats were given 20 visual cue reminder
trials to test retention of the learned rule, whereby rats again were rewarded only for lever
presses corresponding to the illuminated stimulus light. Following the 20 trials, the 120
trial set-shift test began. The animal was required to ignore the light distractions and
respond only on the lever opposite that of their side bias to receive a pellet reward. The
distracting illuminated stimulus light was randomized in its location, and was presented
equally over both levers during the test. Criteria was met when 8 consecutive correct
responses were made. Again, all animals were equally presented with 120 trials in a
testing day. If criteria were not met within the allotted trial limit, the animal was placed in
its home cage and retested the next day.
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Error analysis
Responded errors during the set-shift day were classified as perseverative, regressive,
or never-reinforced. Perseverative and regressive errors are errors that occurred when an
animal followed the visual cue light when they should have responded according to the
new response rule. Perseverative errors occur early in the testing scheme when in a block
of 16 trials, > 6 mistakes were made. Later in the testing regimen when rats began to
adopt the new response rule and 6 or less mistakes were made in a block of 16 trials,
these mistakes were considered regressive. Perseverative errors are an indicator of the
rat’s ability to inhibit a previously learned strategy, while regressive errors indicate the
rat’s ability to maintain a new strategy 151. Never reinforced errors occur when an animal
responds on a lever whereby the strategy was not reinforced by either visual cue or
response discrimination strategies. Never reinforced errors are an index of a rat’s ability
to filter out non-rewarding options

151

. Indicated in Figure 6, only perseverative

opportunities were assessed to determine improvement during the set-shift phase.
Responses made on perseverative opportunities accurately assess both the rat’s ability to
retain the previously rewarding strategy (reflected in the number of errors made on
perseverative opportunities while abiding by the previous rule) as well as the ability to
maintain the new strategy (reflected by the lack of errors). It would be expected that a rat
that fully understood and retained the previous rule before progressing to response
discrimination would make numerous errors on perseverative opportunities at the start of
RD, while the number of errors taper off as RD progresses and the novel rule is adopted.
Set-shifting behavioural measures
Numerous dependent variables are utilized to assess behavioural flexibility.
Traditional measures suggested by Floresco et al (2008) include; number of trials to
criterion and number of errors to criterion

151

. Novel measures in this study include;

improvement in number of incorrect responses, number of incorrect responses in bins of
10, the number of trials in transition between VD and RD transition states (VD transition
is met once the animal made >20% correct responses abiding by the novel rule (indicating
abandonment of the previously rewarding VD rule). RD transition is met once the animal
made >80% responses following the currently relevant RD strategy), and the % likelihood
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to respond incorrectly after being rewarded, considering only trials up until RD criterion
was achieved. Additionally, response latency during RD was evaluated, where response
latency indicates the amount of time that passed between the extension of the lever and
the rat responding on the given lever; this provides a rough measure of speed of
processing.

151

In general, novel behavioural measures were developed by expanding the

number of measurements available to represent the behavioural output data; no
modifications to data output were made. Development of these novel measures was
prompted by unexpected results using parameters suggested in the literature.
2.3.2 Open field (OF)
OF analysis reveals information regarding exploratory tendencies and anxiety-like
behaviours in the rat 198. OF analysis was performed immediately prior to euthanasia, 3.54 m post ET-1/ or control saline injections. Rats were placed in an OF arena (Med
Associates Inc., St. Albans, VT, USA) to explore freely for 10 min. An overhead camera
(Grand and Toy, Canada) mounted on the ceiling with ANY-maze software (Stoelting Co.,
IL, USA) was used for animal detection, tracking, and recording of sessions. Following
10 min of no interruption, rats were removed and placed in their home cage. In between
animals, the arena was cleaned with 70% ethanol to remove scent cues. OF testing
occurred in the rat’s dark, active cycle.
Possible zones of exploration include the central and peripheral zones

199

(Fig. 5)

Total distance travelled in the arena indicates the rat’s tendency to explore a new
environment, while distance travelled in the center zone provides a measure of anxiety 199.
The proportion of time or distance travelled in the periphery of the open field indicates
thigmotaxis, the inherent tendency to be close to the arena walls 199.
2.3.3 Novel object recognition (NOR)
NOR is a test for recognition memory, a type of episodic memory and the rat
equivalent of declarative memory in humans

200,201

. NOR assesses the rat’s ability to

recall if an object has been encountered before, built upon the premise that a rat will
spend more time investigating an object that they have not seen before (novel), and spend
less time with an object they have previously encountered (familiar) 202. NOR does not
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Figure 5: Open field apparatus zones of exploration. In the OF task, rats explore an
empty arena freely for 10 min. Possible zones of exploration include the perimeter and
center zones.
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require food deprivation and does not involve a stressful environment. It provides a quick
and reliable measure to identify difficulties in recognition memory 200.
A complete description of the NOR task is described elsewhere 203. Briefly, rats were
first habituated for 10 min to the OF arena (occurs during OF assessment). Following a 90
min long inter-trial period, two identical objects were presented (familiarization phase) in
which the rat had 4 min to investigate the objects (Fig. 6). After another 90 min inter-trial
period the rat began the novel object recognition phase in which one familiar object (from
the familiarization phase) and a novel object (not presented before) were presented. The
rat again had 4 min to investigate the objects (Fig. 6). A rat with intact recognition
memory should spend more time investigating the novel object

200,203

. This behavior is

described using the discrimination ratio (time with novel object/total interaction time) 203.
A stationary camera (Grand and Toy, Canada) was utilized to record testing sessions. In
between subjects the arena and objects were cleaned with 70% ethanol to remove scent
cues. Rats were placed in their home cage during the inter-trial periods. NOR testing
occurred in the animal’s dark, active cycle.
2.4 Tissue collection, preparation and processing
2.4.1 Tissue preparation
Following the conclusion of behavioural testing, rats were euthanized by an
intraperitoneal injection of 48 mg/mL pentobarbital (Bimeda-MTC, Cambrdige, ON).
Rats were transcardially perfused with 0.01 M phosphate buffered saline (PBS, pH 7.4)
followed by 4% paraformaldehyde (PFA) dissolved in PBS. After tissue extraction, brains
were placed in 4% PFA for 24 h and later added to a 30% sucrose/ddH2O solution until
sectioning. Tissue was flash frozen and sectioned using a cryostat (CryoStar NX50,
Thermo Scientific, MI, USA) at 30 µm and stored in a cryoprotectant solution at -20 oC
until use. Whole brain specimens were cut in coronal sections in series of 10 (300 µm
serial sections).
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Figure 6: Novel objection recognition testing phases. In NOR, rats are first habituated
to an empty arena (during OF testing). During the familiarization phase, two identical
object are presented. Following a 90 min inter-trial period, rats are exposed to one
familiar object (from familiarization) and one novel object.
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2.4.2 Thionine histochemistry
Thionine staining was utilized for detection of cellular nissl substance, indicating cell
populations lost from stroke injury 204. Brain sections were first washed in 0.01 M PBS to
remove residual cryoprotectant. Sections were pre-mounted using 0.3% gelatin on
SuperFrost Plus slides (VWR International, PA, USA) and left to dry for 24 h prior to
staining. Mounted sections were rehydrated through 100% ethanol to ddH20, followed by
30 s exposure to a solution of 0.25% thionine (0.25% thionine acetate salt, 0.28% NaOH,
0.9% CH3COOH (glacial acetic acid) in ddH20). Slides were then dehydrated from 50%
ethanol to Xylene, followed by cover slipping using DePex mounting medium (DePex,
BDH Chemicals, Poole, UK).
2.4.3 Immunohistochemistry
Rat brain coronal brain sections were stained for either activated M1 subtype
microglia, detecting the major histocompatibility complex II (MHC II) molecule (OX-6,
BD Pharmingen, Missisauga, Canada, 554926) or astrocytes, detected glial fibrillary
acidic protein (GFAP, Sigma-Aldrich, Oakville, Canada, G3893). Briefly, sections were
washed thoroughly in 0.01 M phosphate buffered saline (PBS) to clear tissue of
cryoprotectant solution. Free-floating sections were incubated in 1.5% H2O2 for 10 min,
followed by blocking in a horse serum solution at room temperature for 1 h. Sections
were incubated for 24 h at 4 oC in a primary antibody/serum solution (OX6: 1:1000;
GFAP 1:2000 dilution in serum solution) over night. The next day, following 3 x 5 min
washes in 0.01 M PBS, sections were incubated in a biotinylated anti-mouse secondary
antibody solution (1:500 in serum solution, Vector Laboratories Inc., Burlingame, CA,
USA) at room temperature for 1 h. Sections were then incubated in a 2% avidin-biotin
complex (Vectastain Elite ABC Kit, Vector Laboratories Inc., Burlingame, CA, USA) at
room temperature for 1 h. Sections were then incubated in a 0.05% 3,3’-diaminobenziine
tetrahydrochloride (DAB: Sigma) in 1% H202 solution (GFAP, 30 s; OX6, 90 s). After
mounting on SuperFrost Plus slides with 0.3% gelatin and left to air dry overnight,
sections were dehydrated in an ascending series of alcohol, cleared in xylene, and cover
slipped with DePex mounting medium. During staining, rat specimens from each surgical
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group

were

processed

together

to

account

for

any

differences

in

the

immunohistochemistry procedure.
2.4.4 Microscopy imaging and analysis
Stained sections were analyzed using a Nikon Eclipse Ni-E upright microscope with
a Nikon DS Fi2 colour camera head (NIS Elements Imaging) while regions of interest
were identified using a Rat Brain Atlas 205. During imaging, the experimenter was blinded
to the experimental group identification of rat brain slices being imaged to prevent bias
during image selection and analysis.
For OX6 and GFAP tissue analysis, 2x magnification stitched photomicrographs of
30 µm coronal sections were utilized for image analysis. Four separate stitched images
per animal per stain of interest were taken for analysis (AP: 2.04 mm, 1.08 mm, 0.12 mm,
and -2.64 mm relative to bregma). Using ImageJ, ventricle size, striatum size and % area
coverage of OX6 and GFAP immunoreactivity in the striatum, corpus callosum, and
internal capsule were performed. For corpus callosum analysis and striatum/ventricles
size measurements, the affected area was determined by averaging measurements from
three coronal sections; corpus callosum (AP: 2.04 mm, 0.12 mm and -2.64 mm relative to
bregma), striatum/ventricles measures (AP: 2.04 mm, 1.08 mm, and 0.12 mm relative to
bregma). Internal capsule assessment was performed at AP: -2.64 mm relative to bregma,
while individual values were determined by averaging immunoreactivity from both
hemisphere internal capsules. For striatum/ventricle ratio, ratios were determined by
ipsilateral size/contralateral size. For striatum area volume, a value <1 indicates a loss of
ipsilateral striatum content, while a ratio value >1 for lateral ventricle volume indicates an
increase in relative size of the ipsilateral lateral ventricle compared to the contralateral
ventricle. Infarct size quantification in the ipsilateral striatum was performed using
thionine staining by outlining the infarct scar of three coronal sections surrounding the
injury (AP: 2.04 mm, 1.08 mm, and 0.12 mm relative to bregma). Infarct volume means
were calculated using the formula V=ABC/2, whereby V indicates volume, while A, B,
and C indicate the longest dimension of the infarct on the medial-lateral, dorsal-ventral
and anterior-posterior axis, respectively

206

. For each stain, an n=6 for each experimental

group was used.
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2.4.5 Statistical analyses
All statistical analyses were conducted using GraphPad Prism software (GraphPad,
La Jolla, CA, USA) with figure preparation using GraphPad and CorelDraw X7 software.
Data are presented as mean ± SEM, with a statistical alpha of 0.05. Dependent variables
were analyzed using a two-way analysis of variance (ANOVA) with Tukey’s post-hoc
test, or an unpaired-t test.
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Section 3: RESULTS
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3.1 Behavioural assessments
3.1.1 No group differences observed in visual learning task or reminder trials
No differences in weight loss were observed over the testing period due to food
deprivation. To assess the ability of rats to perform a visual cue discrimination task prior
to set-shift testing, rats were trained to follow a visual cue stimulus in order to receive a
food reward. Four months following stroke, the number of trials required to reach
criterion on the visual cue task did not differ significantly between groups (Fig. 7A)
Additionally, no statistical differences were observed in the 20 visual cue reminder trials
(Fig. 7B), tested immediately prior to the set-shift to assess the rat’s ability to retain the
relevant visual cue rule.
3.1.2 F344Tg/ET-1 rats displayed behavioural flexibility with traditional analysis
To assess the effect of unilateral striatal stroke on behavioural flexibility in the
F344Tg, a strategy set-shifting task was utilized (Fig. 4). Four months following stroke,
two-way ANOVA revealed a significant effect of injury (p = 0.0417) when considering
the number of trials required to reach criterion (Fig. 8A) in which WT/ET-1 (81.500 ±
3.984 trials) and F344Tg/ET-1 (82.846 ± 5.163 trials) rats required more trials than
WT/saline (68.333 ± 7.761 trials) and F344Tg/saline (71.625 ± 7.459 trials) groups.
Tukey’s post-hoc analysis revealed no significance. Assessment of the number of errors
made until criterion was reached (Fig. 8B) yielded no statistical differences between
experimental groups.
3.1.3 F344Tg/ET-1 rats displayed reduced perseverative and increased regressive
errors
Analysis of the response discrimination error profile revealed the types of errors
made during set-shift testing, detailing information regarding the ability to maintain a
previously relevant rule, and the ability to adopt a novel rule (set-shift). Perseverative
errors are an indicator of the rat’s ability to inhibit a previously learned strategy,
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Figure 7: No group differences observed in visual learning task or reminder trials.
(A) # trials to criterion in visual cue discrimination, and (B) % correct responses in 20
visual cue discrimination reminder trials. Criterion was achieved when 8 consecutive
correct responses are made in visual cue discrimination testing. Sample sizes for
experimental groups are: WT/saline (n=6), F344Tg/saline (n=8), WT/ET1 (n=10),
F344Tg/ET1 (n=13). Data is represented as mean ± SEM.
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Figure 8: F344Tg/ET-1 rats displayed behavioural flexibility with traditional
analysis. (A) Trials to criterion, and (B) errors to criterion, where criterion was achieved
when 8 consecutive correct responses were made. Sample sizes for experimental groups
are; WT/saline (n=6), F344Tg/saline (n=8), WT/ET1 (n=10), F344Tg/ET1 (n=13). Data
is represented as mean ± SEM. Significance is indicated by; (*) p<0.05 (two-way
ANOVA, Tukey’s post-hoc).
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regressive errors indicate the capacity to maintain a new strategy, and never reinforced
errors indicate the ability to filter out non-rewarding options 151.
Considering the number of perseverative errors, a two-way ANOVA revealed a nonsignificant effect of genotype (p = 0.0501), while Tukey’s post-hoc test revealed
F344Tg/ET-1 rats made significantly less perseverative errors (11.69 ± 2.99 errors)
compared to WT/ET-1 rats (23.50 ± 3.547 errors) (p=0.0437) (Fig. 9A).
Analysis of the number of regressive errors made during the set-shift revealed a
significant effect of genotype (p = 0.0065) in which WT/saline (6.000 ± 0.577 errors) and
WT/ET-1 (11.100 ± 1.963 errors) rats made fewer regressive errors compared to
F344Tg/saline (9.875 ± 1.481 errors) and F344Tg/ET-1 (18.462 ± 1.920 errors) rats. A
significant effect of injury was also observed (p = 0.0012) whereby ET-1 injured rats
made more regressive errors than saline injected rats (Fig. 9B). Tukey’s post-hoc analysis
revealed significant differences in WT/saline vs. F344Tg/ET-1 (p = 0.0005), WT/ET-1 vs.
F344Tg/ET-1 (p = 0.0198), and F344Tg/saline vs. F344Tg/ET-1 (p = 0.0097) in the
number of regressive errors committed (Fig. 9B).
A significant effect of genotype was also observed in the number of never-reinforced
errors committed (p = 0.0057) in which F344Tg/saline (5.000 ± 1.134 errors) and
F344Tg/ET-1 (5.077 ± 1.003 errors) rats made a greater number of errors compared to
WT/saline (1.833 ± 0.543 errors) and WT/ET-1 (2.000 ± 0.919 errors) rats during the setshift (Fig. 9C).
3.1.4 F344Tg/ET-1 rats showed difficulty in retaining previously rewarding strategy
and in maintaining new strategy
Further investigation into the causes of the abnormal F344Tg/ET-1 error profile
(Fig. 9) prompted us to define new ways of looking at the output data. Further
assessments on perseverative response opportunities, those that predict success and
improvement during the set-shift, were analyzed. Group mean changes in the prevalence
of errors on perseverative opportunities were separated into 6 bins (10 trials per bin).
Linear regression analyses of this data represented the decreased likelihood of making
errors as the test progresses, and thus represented the rate of improvement over response
discrimination. Analysis of this data identified three interesting findings (Fig. 10A).
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Figure 9: F344Tg/ET-1 rats displayed reduced perseverative and increased
regressive errors. The error breakdown identifies the number of (A) perseverative, (B)
regressive and (C) never-reinforced errors made by rats during response discrimination
testing. Sample sizes for experimental groups are; WT/saline (n=6), F344Tg/saline (n=8),
WT/ET-1 (n=10), F344Tg/ET-1 (n=13). Data is represented as mean ± SEM. Significance
is indicated by; (*) p<0.05, (**) p< 0.005, (***) p<0.001 (two-way ANOVA, Tukey’s
post-hoc).
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Figure 10: F344Tg/ET-1 rats showed difficulty in retaining previously rewarding
strategy and in maintaining new strategy. Response profiles over response
discrimination testing when considering only perseverative response opportunities (A) is
analyzed by; slope analysis of improvement in number of incorrect responses in bins 1
through 6, (B) number of incorrect responses made in the first bin of 10 trials, (C) number
of trials rats are responding in a transition-like state, (D) and % likelihood to respond
correctly after receiving a reward (E). Sample sizes for experimental groups are;
WT/saline (n=6), F344Tg/saline (n=8), WT/ET-1 (n=10), F344Tg/ET-1 (n=13). Data is
represented as mean ± SEM. Significance indicated by; (*) p<0.05, (**) p< 0.005 (twoway ANOVA, Tukey’s post-hoc).
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Comparing linear regression slopes of improvement revealed a significant effect of injury
using a two-way ANOVA (p = 0.0014) in which WT/saline (-0.200 ± 0.009) and
F344Tg/saline (-0.187 ± 0.012) rats displayed increased improvement compared to
WT/ET-1 (-0.163 ± 0.015) and F344Tg/ET-1 (-0.133 ± 0.011) subjects (Fig. 10B).
Tukey’s post-hoc test revealed significant differences in comparisons of WT/saline vs.
F344Tg/ET-1 (p = 0.0058) and F344Tg/saline vs. F344Tg/ET-1 (p = 0.0182) groups.
To analyze retention of the previously rewarding strategy from visual cue
discrimination, the number of errors made by rats in the first bin of 10 perseverative trial
opportunities was assessed (Fig. 10C). A significant effect of genotype was observed (p =
0.0238) whereby F344Tg/saline (9.000 ± 0.267 errors) and F344Tg/ET-1 (7.923 ± 0.487
errors) rats made fewer errors on average compared to WT/saline (9.833 ± 0.167 errors)
and WT/ET-1 (9.100 ± 0.314 errors) rats, a perceived and abnormal improvement in
F344Tg rats compared to WT. A significant effect of injury was also observed (p =
0.0403) in which ET-1 injured rats made fewer errors compared to saline injected rats
(Fig. 10C), while Tukey’s post-hoc test revealed a significant difference in number of
errors made in WT/saline vs. F344Tg/ET-1 rats (p = 0.0185).
To assess the ability of rats to maintain the new, previously unrewarding strategy, the
number of trials rats responded in a transition phase was determined (Fig. 10D). A greater
number of trials in transition (between VD and RD response strategies (see Methods))
indicate difficulty in maintaining the new strategy. Using a two-way ANOVA, a
significant effect of injury was observed (p = 0.0017) in which WT/ET-1 (16.000 ± 4.240
trials) and F344Tg/ET-1 (23.769 ± 2.840 trials) rats displayed a greater number of trials
in a transition response phase when compared to WT/saline (9.500 ± 2.405 trials) and
F344Tg/saline (7.125 ± 1.807 trials) injected rats (Fig. 10D). Tukey’s post-hoc analysis
revealed significant differences in comparisons of WT/saline vs. F344Tg/ET-1 (p =
0.0303) and F344Tg/saline vs F344Tg/ET-1 (p = 0.0037).
When considering the likelihood of a rat responding incorrectly after making a
rewarding response, a reliable measure of retention for the novel response strategy, a
significant effect of injury was observed (p = 0.0019) in which WT/saline (33.405 ±
3.932 %) and F344Tg/saline (34.994 ± 2.771 %) rats were less likely to make an error
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subsequent to making a correct response, when compared to WT/ET-1 (44.121 ± 2.971 %)
and F344Tg/ET-1 (46.026 ± 2.795 %) rats, indicating that saline injected rats more
reliably retain the novel strategy compared to ET-1 injected rats (Fig. 6E). Tukey’s posthoc test revealed a statistically significant difference in a comparison of WT/saline vs.
F344Tg/ET-1 rats (p = 0.0479) (Fig. 10E).
3.1.5 F344Tg/ET-1 rats displayed delayed reaction response times in RD testing
During set-shifting, average response latency was determined to assess differences in
reaction time. Analyzing average response latency following lever extension during
response discrimination testing using a two-way ANOVA revealed a highly significant
effect of genotype (p = 0.0005) whereby F344Tg/saline (1.443 ± 0.118 s) and
F344Tg/ET-1 (1.714 ± 0.124 s) rats displayed prolonged reaction times during set-shift
testing when compared to WT/saline (1.105 ± 0.146 s) and WT/ET-1 (1.053 ± 0.104 s)
rats (Fig. 11). In addition, Tukey’s post-hoc test identified significance when comparing
WT/saline vs. F344Tg/ET-1 rats (p = 0.0139) and WT/ET-1 vs. F344Tg/ET-1 rats (p =
0.0013).
3.1.6 F344Tg/ET-1 rats did not exhibit dysfunction in recognition memory
NOR was performed to assess the recognition memory abilities of rats 4 months
following stroke injury. In the NOR test, total object interaction time and the amount of
time spent with the novel object relative to the total interaction time (discrimination ratio)
were measured over 4 min in the locomotor box. Overall, no significant differences were
observed in total interaction time (s) (Fig 12B). While all groups spent more time with the
novel object (discrimination ratio > 0.5), no differences were observed between groups
(Fig. 12A)
3.1.7 F344Tg rats displayed an anxiety-like phenotype
OF analysis enables assessment of exploratory phenotypes by analyzing the total
distance travelled, measured over 10 min in the OF box. In addition, assessment of
anxiety-like phenotypes by measurement of the proportion of time spent in both centre
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Figure 11: F344Tg/ET-1 rats displayed delayed reaction response times in RD
testing. Average response latency during response discrimination testing. Values are
averaged over 120 trials, not including trials with omissions. Sample sizes for
experimental groups are; WT/saline (n=6), F344Tg/PBS (n=8), WT/ET-1 (n=10),
F344Tg/ET-1 (n=13). Data is represented as mean ± SEM. Significance is indicated with
asterisks, (*) p<0.05, (**) p< 0.005 (two-way ANOVA, Tukey’s post-hoc)
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Figure 12: F344Tg/ET-1 rats did not exhibit dysfunction in recognition memory. In
the NOR test, total object interaction time (B) and the time spent with novel and familiar
objects (discrimination ratio) (A) were measured over 4 minutes in the locomotor box.
Sample sizes for experimental groups are; WT/saline (n=6), F344Tg/saline (n=8),
WT/ET-1 (n=10), F344Tg/ET-1 (n=13). Data is represented as mean ± SEM.
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and perimeter zones of the arena provided measures of thigmotactic like behaviours.
While no group differences were observed in total distance travelled (Fig. 13A), a twoway ANOVA revealed a significant effect of genotype (p = 0.0050) for % time in the
center zone in which F344Tg/saline (23.667 ± 7.684 %) and F344Tg/ET-1 (9.165 ±
1.965 %) rats spend less time overall in the center zone compared to WT/saline (45.917 ±
12.433 %) and WT/ET-1 (33.574 ± 9.217 %) rats (Fig. 13B). Tukey’s post-hoc test
reveals significant differences in % time in center zone between WT/saline vs.
F344Tg/ET-1 (p = 0.0142) groups (Fig. 13B).

3.2 Immunohistochemistry and histochemistry
3.2.1 Equal infarct volumes from ET-1 in the ipsilateral striatum
To investigate the infarct sizes from ET-1 injection injuries 4 months after injury,
thionine staining for nissl bodies to detect healthy cell populations was utilized. Due to
the advanced recovery of ischemic injuries, infarct scars were often difficult to observe in
rats with thionine staining (Fig. 14B). While saline injected control rats (Fig. 14A)
displayed healthy cell populations visualized using a 10x microscope objective (Fig. 14C),
scarring in ET-1 treated rats (Fig. 14B) was detected by a loss of neurons and presence of
glial supporting cells (Fig. 14D). When comparing infarct volumes between WT/ET-1
(0.7137 ± 0.2347 mm3) and F344Tg/ET-1 (0.4082 ± 0.1459 mm3) treated rats using an
unpaired t-test, no significant differences were observed between genotypes (Fig. 14E).
3.2.2 ET-1 injured rats displayed enhanced microgliosis but not astrogliosis in
injured striatum
To assess the extent of microgliosis and astrogliosis in the injured striatum following
striatal injection of either saline or ET-1 in both WT and F344Tg rats,
immunohistochemistry for OX6 (Fig. 15A-D) and GFAP (Fig. 15E-H) was performed. In
the injured striatum, a two-way ANOVA for % area coverage of OX6 immunoreactivity
revealed a significant effect of injury (p = 0.0193) in which WT/ET-1 (2.524 ± 1.373 %)
and F344Tg/ET-1 (2.968 ± 0.736 %) injected rats displayed enhanced coverage of
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Figure 13: F344Tg rats displayed an anxiety-like phenotype. Total distance travelled
(A) and % time in center zone (B) were measured over 10 min in the Open Field box.
Sample sizes for experimental groups are; WT/saline (n=6), F344Tg/saline (n=8),
WT/ET-1 (n=10), F344Tg/ET-1 (n=13). Data is represented as mean ± SEM. Significance
is indicated with asterisks, (*) p<0.05 (two-way ANOVA, Tukey’s post-hoc).
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Figure 14: Equal infarct volumes from ET-1 in the ipsilateral striatum.
Representative 2x photomicrographs of a saline injected rat (A) and ET-1 injected rat (B)
using thionine histochemical stain. Striatal cellular patterns are visualized at 10x
magnification in the healthy striatum of a saline injected rat (C) and in the residual
ischemic scar in striatum of ET-1 injected rats (D). The infarct volume (mm3) was
determined using infarct area measurements from three coronal sections per rat. The
black outline indicates the region of ischemic scarring (B). Sample sizes for each
experimental group is n=6. Data is represented as mean ± SEM. Scale bar is 1000 µm.
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Figure 15: ET-1 injured rats displayed enhanced microgliosis but not astrogliosis in
injured striatum. Representative 2x photomicrographs of OX6 (A-D) and GFAP (E-H)
immunohistochemical stained rat brain sections. % area coverage of OX6 (I) and GFAP
(J) was measured in the ipsilateral striatum, the location of injury. Focused images
captured at 20x magnification. Sample sizes for experimental each group is n=6. Data is
represented as mean ± SEM. Significance is indicated with asterisks, (*) p<0.05 (two-way
ANOVA, Tukey’s post-hoc). Scale bar is 500 µm.
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activated microglia when compared to WT/saline (0.736 ± 0.345 %) and F344Tg/saline
(0.651 ± 0.240 %) rats (Fig. 15I). While a modest effect of injury was observed with
GFAP immunoreactivity in which ET-1 injured rats had a mild increase in % area
coverage of GFAP signal, no statistical significance was acquired (p = 0.1183) (Fig. 15J).
Tukey’s post-hoc test revealed no significant differences between groups. The % area
coverage for OX6 and GFAP were measured in three coronal sections surrounding the
injury site and were averaged per rat.
3.2.3 F344Tg/ET-1 rats displayed severe white matter microgliosis but not
astrogliosis in corpus callosum
To investigate the chronic responses of ET-1 and F344Tg alone and in
combination in major white matter circuits, immunohistochemical stains for activated
microglia (OX6) and reactive astrocytes (GFAP) were assessed in the corpus callosum of
WT/saline (Fig. 16A,E), F344Tg/saline (Fig. 16C,G), WT/ET-1 (Fig. 16B,F) and
F344Tg/ET-1 (Fig. 16D,H) rats in three coronal sections spanning the corpus callosum. A
two-way ANOVA revealed a significant effect of genotype (p = 0.0012) in which the
total % area coverage of OX6 signal in corpus callosum of F344Tg/saline (2.744 ±
0.755 %) and F344Tg/ET-1 (4.041 ± 0.563 %) was elevated in comparison to WT/saline
(1.274 ± 0.224 %) and WT/ET-1 (1.601 ± 0.357 %) rats (Fig. 16I). Tukey’s post-hoc
comparisons identify increased OX6 immunoreactivity in F344Tg/ET-1 vs. WT/saline
rats (p = 0.0058) and in F344Tg/ET-1 vs. WT/ET-1 rats (p = 0.0157). No significant
differences were observed when comparing GFAP immunoreactivity in WT/saline
(27.333 ± 3.131 %), F344Tg/saline (28.160 ± 3.009 %), WT/ET-1 (28.040 ± 2.934) or
F344Tg/ET-1 (24.558 ± 3.631%) experimental groups (Fig. 16J). Individual means were
calculated by averaging % area coverage from three coronal sections per rat.
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Figure 16: F344Tg/ET-1 rats displayed severe white matter microgliosis but not
astrogliosis in corpus callosum. Representative 2x photomicrographs of OX6 (A-D) and
GFAP (E-H) immunohistochemical stained sections. % area coverage of OX6 (I) and
GFAP (J) immunoreactivity in the corpus callosum was measured. Focused images
captured at 20x magnification. Sample sizes for each experimental group is n=6. Data is
represented as mean ± SEM. Significance is indicated with asterisks, (*) p<0.05, (**)
p<0.005 (two-way ANOVA, Tukey’s post-hoc). Scale bar is 500 µm.
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3.2.4 F344Tg rats displayed enhanced microgliosis but not astrogliosis in internal
capsule
The internal capsule was also assessed for OX6 and GFAP immunoreactivity for
the aforementioned reasons, assessed in WT/saline (Fig. 17A, E), F344Tg/saline (Fig.
17C, G), WT/ET-1 (Fig. 17B, F) and F344Tg/ET-1 (Fig. 17D, H) rats in one coronal
section containing the internal capsule. A two-way ANOVA revealed a significant effect
of genotype (p = 0.0165) in which the total % area coverage of OX6 signal in internal
capsule of F344Tg/saline (2.619 ± 0.815 %) and F344Tg/ET-1 (3.424 ± 0.741 %) was
elevated in comparison to WT/saline (1.436 ± 0.391 %) and WT/ET-1 (1.471 ± 0.265 %)
(Fig. 17I). No significant differences were observed when comparing GFAP
immunoreactivity in WT/saline (18.007 ± 3.570 %), F344Tg/saline (18.805 ± 2.116 %),
WT/ET-1 (18.380 ± 2.986 %) or F344Tg/ET-1 (16.352 ± 1.829 %) experimental groups
(Fig. 17J). Tukey’s post-hoc test revealed no significant differences between groups.
Individual means were calculated by averaging % area coverage from both hemispheres
of one coronal section per rat.
3.2.5 Striatal cellular atrophy and ventricular enlargement following focal stroke
injury
Tissue atrophy and lateral ventricular enlargement are frequently used to assess
striatal stroke severity. To assess the extent of striatal atrophy in the ipsilateral striatum
relative to the uninjured contralateral striatum within the same rat in saline (Fig. 18A) and
ET-1 (Fig. 18B) injected rats, total area measurements of both striatum were determined
(Fig. 18C). A two-way ANOVA revealed a significant effect of injury (p = 0.0087) in
which WT/ET-1 (0.889 ± 0.061) and F344Tg/ET-1 (0.884 ± 0.022) injections resulted in
reduced ratios of ipsilateral/contralateral striatum size compared to WT/saline (0.983 ±
0.015) and F344Tg/saline (1.001 ± 0.027) injections, implying a decrease in size of total
striatum area of the injured hemisphere in ET-1 injured rats. Tukey’s post-hoc test
revealed no significant differences between groups. Individual means were determined by
averaging three coronal sections from each rat.
The magnitude of ventricular atrophy in the ipsilateral lateral ventricle, adjacent to
the injured striatum, was measured relative to the contralateral lateral ventricle within the
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Figure 17: F344Tg rats displayed enhanced microgliosis but not astrogliosis in
internal capsule. Representative 2x photomicrographs of OX6 (A-D) and GFAP (E-H)
immunohistochemical stained sections. % area coverage of OX6 (I) and GFAP (J)
immunoreactivity in the internal capsule was measured. Focused images captured at 20x
magnification. Sample sizes for experimental group is n=6. Data is represented as mean ±
SEM. Significance is indicated with asterisks, (*) p<0.05 (two-way ANOVA, Tukey’s
post-hoc). Scale bar is 500 µm.
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Figure 18: Striatal cellular atrophy and ventricular enlargement following focal
stroke injury. Representative 2x stitched photomicrographs of a saline injected (A) and
ET-1 injected (B) rat. The ratio of ipsilateral/contralateral striatum area (C) and ratio of
ipsilateral/contralateral lateral ventricle area (D) was measured. Sample sizes for
experimental group is n=6. Data is represented as mean ± SEM. Significance is indicated
with asterisks, (*) p<0.05, (**) p< 0.005 (two-way ANOVA, Tukey’s post-hoc). Scale
bar is 1000 µm.
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same animal (Fig. 18A,B). Individual means were determined by averaging three coronal
sections from each rat. Total area measurements of both lateral ventricles were
determined (Fig. 18D). A two-way ANOVA revealed a significant effect of injury (p =
0.0238) where WT/ET-1 (1.493 ± 0.188) and F344Tg/ET-1 (1.381 ± 0.199) injections
caused increased ratios of ipsilateral/contralateral lateral ventricle size compared to
WT/saline (1.016 ± 0.076) and F344Tg/saline (1.132 ± 0.085) injections. This result
implies an increase in lateral ventricle area on the hemisphere ipsilateral to the injury in
ET-1 injured rats. Tukey’s post-hoc test revealed no significant differences between
groups.
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Section 4: DISCUSSION
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4.1 Summary of findings
In the present study we tested the chronic behavioural and histological
consequences of inducing subcortical stroke in aged F344Tg rats in an effort to better
understand the pathological interactions of stroke and AD-like pathology in chronic
injury. In our study, F344Tg/ET-1 rats displayed features of increased behavioural
inflexibility, while F344Tg rats displayed an anxiety-like phenotype, increased response
latencies, and increased activated microglia in white matter when compared to WT rats.
These pathological displays were mildly enhanced further with the comorbidity of a
subcortical stroke. ET-1 injury alone displayed few features of behavioural inflexibility,
increased activated microglia in the ipsilesional striatum, and enhanced striatal atrophy
with ventricular enlargement when compared to stroke free rats. A modest increase in ET1 induced GFAP immunoreactivity was observed at the lesion site.
To our knowledge, our study is the first to investigate behavioural flexibility in
combination models of AD/stroke. A past AD/stroke model utilized by Whitehead and
colleagues identified learning and memory impairments

103

. Synergistic memory

impairments have also been observed in a comorbid chronic hypoperfusion injury/Aβ
injection rat

207

. Regarding behavioural flexibility, studies utilizing operant-based

behavioural flexibility testing frequently include neural circuitry dissociation studies
150,151

or have utilized stressors including stress or post-traumatic stress disorder (PTSD)

models

208,209

. Past studies have employed bilateral ET-1 induced mPFC stroke revealing

behavioural inflexibility characteristic of a perseverative phenotype 153,210 consistent with
the observed role of the mPFC in this process. Following chronic bilateral common
carotid artery occlusion (BCCAo), impairments in intradimensional shift (IDS)
behavioural flexibility was observed

211

. AD studies utilizing rodents have observed

impairments in behavioural flexibility characteristic of prefrontal dysfunction
consistent with clinical studies of AD

140,214

212,213

,

. Additional studies utilizing behavioural

flexibility testing in rodent models of AD/stroke are integral in our understanding of the
role of executive functions in comorbid brain pathology.
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4.2 F344Tg/ET-1 rats display perturbed behavioural flexibility
On the visual cue discrimination task, no significant differences were observed
between groups, indicating that all groups equally learn the discrimination task. This
finding is important in that it proves the combination of ET-1 in the F344Tg is a reliable
model system to test behavioural flexibility. Using the classically described behavioural
measures suggested in the literature

148

, a lack of dysfunction in F344Tg/ET-1 rats was

first observed (Fig. 8). While error profile analysis indicated that WT/saline, WT/ET-1,
and F344Tg/saline treated rats had expected error response profiles characteristic of high
number of perseverative errors with low regressive errors, F344Tg/ET-1 treated animals
in fact exhibited low numbers of perseverative and high regressive errors (Fig. 9)
indicating a more rapid abandonment of the previously rewarding strategy, and an
enhanced difficulty in maintaining the novel set-shift strategy, respectively.
Using novel analysis that we developed assessing perseverative response
opportunities (Fig. 10), we confirm the poor retention of the previous strategy by showing
that F344Tg/ET-1 rats made significantly fewer mistakes in the initial stages of RD,
indicating a more rapid dissociation from the previously rewarding strategy (Fig. 10C). It
could be suggested that this phenomenon is a result of F344Tg/ET-1 rats insufficiently
understanding the value and security of reward that is attached with the previously
rewarding strategy, a phenomenon coinciding with issues of latent inhibition, the animal’s
ability to ignore stimuli or strategies that provide no reward

215

. For example, during

visual cue discrimination training, rats learned to a) associate the light stimulus with a
reward, while also learning that b) the absence of a light stimulus provided no reward
(termed, learned irrelevance). During early stages of the set-shift, it would be expected
that competent animals carry over both the learned rule (follow the light) and the learned
irrelevance. Floresco and colleagues suggest that the perceived improvement in early
stages of set-shifting may be the consequence of perturbed latent inhibition due to an
improper understanding of the irrelevance of non-rewarding strategies

148

. The outlined

phenomenon has been observed in rats with NAc shell lesions injured prior to
discrimination training and in studies utilizing dorsomedial striatum (DMS) inactivations
148,216

. These findings reinforce the role of NAc and DMS in learned irrelevance and

suggest that damage to these regions reliably predict this unique error profile. An
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additional argument for the observed decreased perseverance in F344Tg/ET-1 rats may be
that the initial discrimination task was learned insufficiently. However, no differences
were observed in trials to reach criterion on the visual cue discrimination task (Fig. 7),
indicating the discrimination task was learned equally.
Significant numbers of regressive errors indicate the inability to maintain and
consolidate the novel strategy, an observation in combined F344Tg/ET-1 rats (Fig. 9).
Using our suggested novel analysis approaches (Fig. 10), it was observed that
F344Tg/ET-1 rats improved significantly less over the test duration, a direct measure of
the ability to maintain and abide by the novel rewarding strategy (Fig. 10A-B). Analysis
of the number of trials that rats respond in a transition state, as well as assessing the
likelihood that rats make recurrent correct responses confirm the findings that
F344Tg/ET-1 rats display significant difficulty in maintaining the rewarding strategy (Fig.
10D-E). Similar findings were observed by Ragozzino and colleagues in which high
numbers of regressive errors were observed following bilateral tetracaine infusions (a
Na+ channel blocking anaesthetic) into the DMS compared to saline infusions, indicating
an inability to maintain the currently relevant strategy due to interrupted DMS function
217

. While never-reinforced errors indicate an impairment in the rat’s ability to select a

novel strategy and filter out non-rewarding response options

209

, we have observed an

effect of genotype in which F344Tg rats make more never-reinforced errors compared to
WT rats (Fig. 9). It is possible that subtle influences of APP affect white matter circuitry
involved in this behaviour, though this is not exacerbated by the addition of an ET-1
mediated lesion in the striatum.
We used performance on the strategy set-shifting task as an indicator for integrity
of the neural circuitry that mediates behavioural flexibility in the intact rat brain. The
observed latent inhibition as observed in F344Tg/ET-1 rats suspects damage of neural
nuclei of or connecting regions of the nucleus accumbens, or the dorsomedial striatum.
Considering initial ET-1 induced ischemic damage was restricted to the dorsal striatum,
we suspect that damage spreading peripheral to the injury in F344Tg/ET-1 rats had
resulted in juxtaposed neural regions being affected that may have resulted in the
observed behavioural abnormalities. The dorsal striatum plays a valuable role in
executive functions including decision making, goal-directed behaviours and stimulus-
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response learning

218

. Overall, injury to the dorsal striatum may perturb these functions,

particularly in the acute phase after stroke injury.
4.3 No observed dysfunction in recognition memory
Assessment of recognition memory in the NOR task revealed that all groups
displayed working recognition memory, evidenced by the discrimination ratio (Fig. 12).
Past studies of NOR in the APPswe/PS1dE9 AD model observed severe impairments in
NOR in 24 m Tg rats compared to WT 58, effects likely due to the AD phenotype and not
age, as age in rat studies have been shown to play little role in NOR functions

219

.

Selective ischemia of the corpus callosum by ET-1 has been observed to cause NOR
deficits, validating the role of white matter connectivity in NOR performance 220. In rats,
NOR is a task reliant upon neural regions including the mPFC, hippocampus, and medial
dorsal thalamus

126

. Subcortical stroke injury is likely to impede normal performance of

axonal function in cortical-subcortical white matter fiber tracts by axonal injury and
downstream cortical loss of these brain regions. In our study, it is possible that ET-1
simply did not damage these circuits, or recognition memory is a resilient behaviour
uninfluenced by subtle injuries of subcortical stroke and APP expression in axonal tracts.
It may also be possible that deficits appeared in the acute injury phase but were resolved
by the time of testing. A past model of microinfarct stroke observed that while NOR
deficiencies were observed within the first 2 w post-stroke, NOR performance was
returned to baseline at 28 d post-injury

221

, suggesting NOR performance may only be

impaired in acute phases of stroke. Clinical observations in VCI, a form of cognitive
impairment characterised by subcortical vascular lesions revealed executive function
deficits are often observed while memory functions are spared

222,135

, a commonality in

our study.
4.4 F344Tg rats displayed an anxiety-like phenotype
A modest, non-significant decrease in exploratory behaviour was observed in
F344Tg rats indicated by total distance travelled in the OF (Fig. 13A). Total distance
travelled is a well utilized measure of exploratory tendencies

199

. Additionally, F344Tg

rats displayed a significant reduction in total time spent in the center zone of the OF (Fig.

68

13B) in which active avoidance of the center zone is a reliable measure of an anxiety-like
phenotype

199,223

. Exploratory tendencies are also often decreased in anxious rodents

224

.

The trend of reduced exploration in F344Tg rats may in part be due to a heightened stress
or anxiety response in F344Tg rats.
Past studies of AD/stroke comorbidity in rodents have failed to assess anxiety and
exploratory phenotypes. Investigations of anxiety phenotypes using OF post-stroke reveal
less time spent in the center zone

210

, while it has been suggested that no changes in OF

anxiety occur following damage to the caudate putamen
have observed no change in total exploration

210

225

. Post-stroke studies typically

, while focal white matter stroke of the

corpus callosum also revealed no differences in locomotion

220

. APdE9 mutated mice

have shown hyperactivity and increased exploratory tendencies compared to WT controls
226

, while observed hyperactivity phenotypes in only aged APPswe/PS1dE9 transgenic rats

are thought to be a result of disinhibition due to hippocampal and cortical injury from Aβ
pathology

58

. Reduced overall locomotion in the OF has also been used to indicate a

depressive-phenotype 227. Chronic mild stress in rodents is shown to influence depressive
and anxiety-like phenotypes by reduced exploration in the OF task
age-related decline in exploratory behaviours is observed

219

228

while an overall

. Thus, influences of stress

from testing and food deprivation combined with age may contribute to overall decreased
exploration in our study. Key circuitry influencing anxiety-like phenotypes in the rat
involve the basolateral amygdaloid nucleus (BLA), ventral hippocampus, and lateral
entorhinal cortex

127

. It may be speculated that influences of APP on axonal health may

influence circuitry mediating this behavioural phenotype, an effect mildly exacerbated by
potential further axonal injury due to stroke.
4.5 Activated microglia and astrocytes within the infarct
It was hypothesized that stroke in the F344Tg rat may cause persistent
inflammatory changes and growth of the infarct at the infarct site. Thionine
histochemistry was used to assess infarct volume, while OX6 and GFAP
immunoreactivity was used to assess the presence of activated microglia (microgliosis)
and activated astrocytes (astrogliosis), respectively, in the injured striatum. Infarct sizes 4
m post-ET-1 stroke in the lesioned striatum were shown to be equal in F344Tg and WT
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rats (Fig. 14E). While thionine histochemistry at acute time points typically reveals pale
regions of cellular loss, infiltration of glial cells to form a glial scar network are
visualized in thionine staining as patches of smaller blue nuclei, evident of glial cell
populations in the advanced recovery stages (Fig. 14D). Quantifying infarct sizes at 4 m
post-injury proved difficult, as remodelling and recovery at the injury site evidently acted
to restore the original striatal morphology. Additionally, defining infarct borders for OX6
and GFAP stains proved unreliable and were therefore not included in quantification.
However, overall quantification of area coverage of OX6 and GFAP in the lesioned
striatum was performed.
A non-significant increase in chronic astrocytic gliosis in the ipsilateral striatum was
observed in ET-1 injured rats, an effect not exacerbated in F344Tg rats (Fig. 15J).
Reactive gliosis is an integral aspect to support regeneration following a stroke lesion,
acting as trophic support and to seal off the lesion from its surroundings 229. Alternatively,
formation of glial scarring is shown to perturb axonal growth and repair following injury
230,231

. Thus, stroke injury to penetrating axonal tracts through the striatum may likely

have persistent functional loss up until 4 m post-injury, offering a possible explanation for
persistent behavioural alterations. It may be speculated that in the chronic injured striatum,
the loss of astrocytic-axonal coupling and neurovascular unit integrity, often observed in
regions of stroke scarring

232

may inhibit astrocytic support of the axons, preventing

optimal axonal function. Analysis of OX6 immunoreactivity in the lesioned striatum of
ET-1 injured rats revealed persistent M1-subtype activated microglia, an effect not
worsened in F344Tg rats (Fig. 15I). Past studies following photothrombotic stroke
identified no microglial activation at 60 d post injury in the infarcted region, while GFAP
immunoreactivity remained high in the form of a glial scar 233. A landmark study utilizing
AD/stroke combination models observed increased thionine, OX6, and GFAP signal in
the ipsilesional striatum 28 d post striatal ET-1 induced stroke in combined injured rats 103.
While chronic assessments of inflammation in experimental rat studies is infrequent
234

, Keiner and colleagues observed decreased microglial activity in the infarct periphery

at 42 d post-ischemia

235

. In contrast, clinical studies have observed persistent microglial

responses in the infarct up to 150 d post-injury 236. After a 6 m follow-up after subcortical
stroke, some patients display persistent microglial activation at the site of injury, though

70

this recovers significantly compared to 2 w post-injury

234

. Persistence in microglial

activation after a single injurious stimulus has been suggested to be due to production of
ROS and cytokines that continuously act through cytokine signalling between glial cells
and microglia, in addition to continued cleanup from dying cells

237

. While microglial

activation has been observed to diminish in the infarct with recovery, persistent
inflammation in distant white matter circuits connected to and affected by the initial
stroke injury has been observed at a 6 m time-point in the brainstem 234. Thus, it is likely
that distant white matter damage may be present in circuitry that has been affected by the
stroke injury up to 4 m post-stroke.
4.6 Remote white matter injury and behavioural dysfunction
An observed effect of genotype was observed for F344Tg rats in overall burden of
OX6 immunoreactivity in the corpus callosum (Fig. 16I) and internal capsule (Fig. 17I),
effects increased modestly in the presence of subcortical stroke. Past studies have
identified remote white matter injury and remote degeneration of gray matter following
subcortical stroke. Chronic observations at 3 m

238

and 6 m

239,240

post-subcortical stroke

have identified persistent changes in collasal white matter fiber tracts 239 with downstream
degeneration of cortical regions associated with fibre tracts damaged by the subcortical
injury

240

. Chen and colleagues suggested that remote changes are due to the loss of

afferent synaptic input from distal regions, or as a result of retrograde degeneration of
axons

241242

or their myelin sheath

242

. Studies utilizing magnetic resonance diffusor

tensor imaging (DTI) use the fractional anisotropy (FA) index as a measure of the
integrity of white matter fibre tracts

234,243

in which reduced FA values indicate axonal

loss and Wallerian degeneration, the process of degeneration of the distal neuron portion
typically observed after injury or stroke

234,243,244

. Further, studies have suggested that

histologically, MHC Class II expressing microglia (OX6+) may be a histological correlate
of Wallerian degeneration

245

. Thus, it may be speculated that the presence of OX6 in

white matter may in fact be responding to enhanced axonal tract damage in the chronic
stages following white matter injury. Following experimental TBI, correlations were
made between white matter injury, neurofilament SMI-32 immunoreactivity and
paralleled M1-subtype microglia increases in the corpus callosum in which neurofilament
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SMI-32 is an overall marker of axonal health

43

. Other studies have observed activated

microglia in major white matter tracts in the rhesus monkey with age, suspected to be
responding to white matter degeneration

246

. It has also been observed that M1 microglia

play a role in phagocytising products of myelin degeneration

245

. Thus, it is further

supported that M1 microglia in white matter after injury are responding to damage, and
therefore may be a suitable assay for overall axonal and myelin health.
It is speculated that the enhanced M1 inflammatory response in white matter
circuitry of the rat at 4 m post-subcortical stroke in F344Tg rats reflects an induced
recruitment of phagocytic inflammatory microglia to an environment of upregulated APP
and its enzymatic by-products, including Aβ. Increased levels of Aβ may act to promote
neurotoxicity, leading to axonal or myelin breakdown with subsequent recruitment of M1
microglia. A chronic state of axonal or myelin damage may promote the release of proinflammatory cytokines with the potential to further damage fiber tract integrity. These
inflammatory cytokines may also negatively affect oligodendrocyte populations

247

, an

effect that would worsen myelin degeneration. In addition, our findings show that this
process may be driven by the ET-1 injury, resulting in heightened persistent inflammation
in distant white matter tracts. Future studies may aim to assess myelin and axonal health
to help answer these questions. In addition, the contributions of these M1 microglia in
influencing recovery or promoting further fiber tract damage must be investigated. The
presence of these long-term inflammatory responses may act to promote persistent
neurodegeneration and progressive cognitive decline, as predicted in Thiel’s model 5. Past
studies have observed increases in activated microglia in the corpus callosum white
matter concomitantly with increased cognitive issues 246. Interesting findings by Kim and
colleagues identified that following stroke induced by BCCAo, impairments in IDS
behavioural flexibility were found in conjunction with increased OX6 immunoreactivity
in white matter tracts of the forceps minor and a mild increase in the rostral corpus
callosum

211

. These observations parallel findings from our study, reinforcing the likely

importance of white matter integrity in behavioural flexibility. Determining the functional
behavioural effects that this persistent and heightened inflammatory response in white
matter has on distant sites is of great value.
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Clinical studies observe damage to the interhemispheric corpus callosum to be a
strong predictor of disturbances in processing speed and cognition

123,241,248

, while

executive dysfunction is a cardinal sign in leukoaraiosis of the periventricular white
matter, a condition characterized by compromised white matter function of the
interhemispheric fibre tracts

142,249

. Interhemispheric white matter tracts such as the

corpus callosum and thalamic projections are known to contain subcortical-cortical fiber
tracts, tracts known to be integral in sufficient processing speed and executive functions
250

, behaviours observed to be perturbed in cSVD

248

. Clinical studies of subcortical

ischemia frequently present with both disturbed executive functions and perturbed mental
processing speed 141,142,249,251, functions that require structural and functional connectivity
to distal brain regions. Thus, disruption of these integral fiber tract networks that
interconnect cortical-subcortical neural substrates by means of subcortical ischemia or
APP influences may realistically promote similar behavioural disturbances as observed in
clinical studies. In our study, F344Tg rats inherently had slower response times, an effect
modestly enhanced by the subcortical stroke (Fig. 11). Reaction time is a complex
process requiring efficient nerve conductance of electro-chemical signals through white
matter circuitry of visual and subsequent motor pathways

252

. It may be speculated that a

slowing of axonal impulses, synaptic transmission or deficient sensory signalling may
impair speed of signal conductance, thus increasing time between presentation of a visual
stimulus and an evoked motor response. Perhaps basal levels of APP or APP products
including Aβ act to perturb axonal health due to enhanced inflammatory mediator and
immune cell recruitment, while microglial recruitment may further cause inflammatory
and stress changes in the environment. White matter injury due to stroke may further
perturb this process through damage to axons, loss of myelin integrity, and possible
production of axonal swellings that may promote slowing of conductance. Increased
response latencies and reduced locomotion have been observed following PFC-NAc
lesions in the rat 147, similar fiber tract circuitry that may have been affected in our animal
models. Thus, it is plausible that a local subcortical infarct in the basal ganglia may
influence white matter integrity both locally and distant, possibly into the contralateral
hemisphere, furthering an already inflammatory state of the white matter induced in the
F344Tg rat. Spreading of white matter damage to the contralateral hemisphere may
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influence behaviours including set-shifting that are thought to require bilateral insults to
consolidate behavioural dysfunction.
4.7 Unilateral stroke may influence cognition through bilateral white matter
An interesting finding in set-shifting was observed in which F344Tg/ET-1 rats
displayed behavioural dysfunction typically only observed in studies utilizing bilateral
injuries of set-shifting neural circuitry. While human executive function is highly
lateralized, this is thought to not be the case in rodents

150

whereby both hemispheres

contribute aspects of these behaviours. Thus, frequently rodent studies will utilize
bilateral lesions or inactivations of a selected brain region 153,253. Considering a unilateral
lesion was utilized in our study, it is interesting that a subtle bilateral effect was observed.
In addition, bilateral increases in internal capsule OX6 immunoreactivity was observed
(Fig. 17I), further supporting a role of unilateral injury in influencing bilateral white
matter changes. Rodent studies have observed that rats are typically unaffected in tasks of
cognitive performance if damage is confined to only one hemisphere 254, a key difference
observed from the highly lateralized human brain that is influenced negatively following
unilateral ischemia

254

. In a clinical study with post-stroke assessment at 3 m, white

matter injury was observed in both hemispheres while those who exhibited worsened
white matter injury in the contralateral hemisphere correlatively displayed worsened
executive functions, perturbed attention and slower processing speed compared to healthy
individuals

238

. It is possible that a unilateral subcortical injury causing bilateral white

matter injury in the rat may in fact be sufficient to negatively influence tract-specific gray
matter targets of the contralateral hemisphere, a salient enough effect to cause
behavioural inflexibility to the same magnitude that normally requires bilateral lesions.
4.8 Additional factors influencing white matter integrity
OX6 immunoreactivity was also observed in white matter of aged WT rats. Aged rats
are observed to have a natural increase in the level of OX6 immunoreactivity in the
corpus callosum and internal capsule
246

255

, a similar trend observed in the rhesus monkey

. Natural facets of aging may result in degeneration or renewal of axon components and

white matter, resulting in basal levels of required microglial cleanup. Microglia have
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basal duties of synaptic pruning and repair 42, and thus baseline levels would be expected.
It may be possible that systemic inflammation caused by stress, including stress from
food deprivation 256, may manifest itself as microglial activation in the brain and possibly
in white matter circuitry

257

. Thus, basal levels of OX6 microglia in white matter of WT

rats may be in part due to age or stress induced by testing and food deprivation protocols.
4.9 No differences observed in astrogliosis in white matter
Based on past studies from our lab, an expected increase in astrogliosis coverage was
expected in the white matter, however no group differences were observed in GFAP
immunoreactivity in white matter circuitry of the corpus callosum or internal capsule (Fig.
16J, 17J). Reactive gliosis is traditionally observed as a defensive process in brain
pathology that is thought to be responsible for remodelling, and is shown to react and
contribute to the process of neuroinflammation

229,258

. While much support has

accumulated for the role of reactive astrogliosis in neurodegeneration and inflammation,
more recent studies have shown support for the occurrence of astroglial atrophy in
neurodegenerative diseases

258

in which a general reduction in function of astrocytes is

thought to play an important role in neurodegenerative disease progression

229

. Clinical

observations in AD identify atrophy of astrocytes in which morphological changes permit
reduced coverage of synapses, loss of CNS homeostatic balance, and overall compromise
of neuronal health and survival

258,259

. This loss of astrocytic coverage may impair

synaptic signalling due to the importance of astrocytic function in neurotransmitter
clearance following nerve conductance 259. These reductions in astrocytes are observed in
early stages of AD, and loss of homeostatic support may be responsible for early
cognitive changes

229

. Past AD models including the 3xTg-AD have observed atrophy of

astrocytes preceding the presence of Aβ deposition 260, while astrogliosis was observed in
the progressive stages when astrocytes were in association with Aβ plaques and CAA
deposits

260

. A reduction in GFAP positive astrocytes may also act to perturb

neurovascular unit performance with reduced synaptic support

258

. Reduced support to

axonal white matter projections in the brain may contribute to worsened axonal health
and axonal performance, features that may be aligned with and reflected in increased
white matter microglial activation and poorer behavioural outcomes, as observed in our
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F344Tg/ET-1 rats. An unexpected equivalent GFAP signal in control rats may be the
result of inherent increases in astrogliosis often observed in aged animals 261.
4.10 Striatal cellular atrophy and ventricular enlargement following stroke injury
An increased size of lateral ventricles in the ischemic ipsilateral hemisphere has been
observed to increase over the recovery process into the chronic stage as recovery induced
reconstruction and cellular atrophy begins

262

. In our study, it was expected that ET-1

striatal injury groups would abide by this phenomenon, and this was observed.
Experimental studies have identified enlargements in the volume of the ipsilateral lateral
ventricle and overall tissue loss in the affected hemisphere following small reversible
MCAo, often observing decreases in overall hemisphere size of 4-20% dependent on
ischemia size

254

. In a comorbid Aβ/ET-1 rat model, both lateral ventricular enlargement

and striatal tissue loss were observed 193. In the elderly, ventricular enlargement has been
correlated with poorer cognitive performance, indicative of cerebral atrophy adjacent to
the ventricles 263, as well as correlated with the transition from mild cognitive impairment
(MCI) to AD 264. In MRI studies, ventricular volume is often used as a measure of overall
ischemic damage 84. While striatal and whole brain swelling due to edema is observed in
the acute stages of ischemia, shrinking of affected regions is observed in the chronic
remodeling stages

262

. Typical clinical presentations in stroke patients reveal an average

tissue loss of less than 15% of the volume of the affected hemisphere in patients who
survive their ischemic injuries 254.
4.11 Speculation of damage in acute injury stages
In the acute phase of injury, it may be speculated that the presence of both APP and
possible Aβ stressors in the presence of stroke injury may have led to enhanced
inflammatory responses causing enhanced inflammatory mediator release and immune
cell activation. ET-1 induced damage to both gray and white matter of the striatum will
occur whereby damage to traversing white matter tracts may have led to axonal
degeneration and recruitment of APP around the infarct border. Due to the numerous
factors of the ischemic region including hypoperfusion, it is speculated that increased
APP translocation and degradation of APP at the infarct may have produced more Aβ at
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the injury site. Here, increased Aβ release may have caused hypoperfusion, excitotoxicity,
and further promote neuronal degeneration, cellular stress, and enhanced inflammatory
properties in the ischemic region. Possible increases in striatal cellular death may cause
increased white matter involvement with worsened remote injury and behavioural
outcomes. It is speculated that the combination of injurious factors may drive a normally
acute injury into a persistent, chronic state of inflammation. Following stroke injury,
damage to the neurovascular unit, particularly astrocytic-blood vessel interactions, may
alter glymphatic drainage in the brain parenchyma. In the healthy brain, glymphatic
perivascular clearance acts to flush cerebrospinal fluid through the interstitial space of the
brain parenchyma to clear toxic metabolites back into the bloodstream 37. Impairments in
glymphatic clearance from stroke injury may lead to toxic metabolite buildup in the brain
parenchyma, including Aβ metabolites, being ineffectively cleared

221

. In a model of

mutated APP, it may be speculated that enhanced Aβ release into the brain parenchyma
may add to the toxic load during glymphatic dysfunction, leading to an increased
recruitment of inflammatory cells. If persistent, inflammatory cell presence may persist
into the chronic phase. Due to ischemia, death or aggravation of astrocytes may further
promote glymphatic dysregulation. Assessment of astrocyte coverage and aquaporin-4
channel localization would further our understanding of the role of ischemia in
glymphatic dysregulation in the acute phase of stroke. However, this dysfunction may
have resolved before the chronic phase of injury. Future experiments should aim to study
the interactive combination of mutated APP and subcortical ischemia at earlier time
points to determine if acute effects lead to more severe injury that persists chronically.
4.12 Further considerations in development of a pre-clinical AD/stroke rat model
In this study, aged animals are used in an attempt to recapitulate natural aging and
injury recovery in aging. While age is one of the most important independent risk factors
for stroke

84

and AD

156

, age predisposes an individual to poorer functional recovery and

worse outcomes after stroke

265,266

. At the site of stroke injury, a slower infiltration of

macrophages with subsequent delayed tissue removal has been observed in 20 m rats
when compared to young rats
brain are increased

84

161

, while basal inflammatory cytokine levels in the aged

, both of which may contribute to worsened outcome following
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injury. In addition, aged rats exhibit slower angiogenesis into recovering ischemic regions,
leading to poorer vascular and functional recovery

267

. However, very few studies utilize

rodents over the age of 15 months in interventional stroke studies 265. Stroke studies have
observed more severe behavioural and neurological injury following ischemia in aged
animals, translating into persistent deficits not observed in young rats

225,254

. Overall to

improve the pre-clinical usage of models and the predictive validity of therapeutic studies
in neurodegenerative research, aged animals are recommended as injury studies in young
animals may poorly translate to pathology observed in elderly human patients

254,268

.

While numerous past studies have identified interactions between ischemic stroke
and AD pathology in the acute phases of injury up to 30 days

162

, few have assessed the

chronic influence of allowing the conditions to fester in an in vivo model. It may be
speculated that prolonging the opportunity for pathological interactions between Aβ and
stroke damage may cause persistent and heightened responses through inflammatory
processes. While much focus is placed on acute time points in injury and recovery,
chronic behavioural outcomes in the clinical setting are extremely valuable and preferable
in understanding therapeutic potential

129

. Persistent neuroinflammation is a hallmark in

many neurodegenerative conditions including AD
Amyotrophic Lateral Sclerosis

270

59

, Parkinson’s disease

and in the chronic stages following TBI

20

269

,

. Clinical

studies have identified chronic degeneration of motor fibre tracts up to 3 months and
motor deficits worsening up to 4 and 12 weeks in patients with subcortical infarcts 271. In
moderate human TBI, inflammation in the corpus callosum is shown to persist for many
years after the initial trauma in conjunction with persistent tissue atrophy and
degeneration of axons

20,272

and persistent microglial activation associated with pro-

inflammatory cytokines at the lesion site for months post-injury 273. Experimental models
have identified a peak inflammatory profile at 60 days post-injury with persistent
inflammation up to 180 d post-moderate TBI 274. Wang and colleagues suggest that while
acute inflammation may be protective, chronic inflammation may worsen injuries

43

,a

reality that was important in the development of this study. It is speculated that the
chronic behavioural differences may reflect damage from secondary degenerative
processes including persistent inflammation.

78

The use of male rats serves an important consideration in developing this pre-clinical
AD/stroke model due to demonstrated benefits of estrogen and progesterone in offering
neuroprotection in studies of cerebral ischemia and AD

275,276

. Past studies using

transgenic rat AD models have highlighted no observed differences in Aβ pathology or
cognitive analyses between male and female rats 31. The utility of female rats in the future
to validate the current findings in male rats will aid in understanding the influences of
these sex differences in injury and recovery.
4.13 Pitfalls and future studies
A lack of power was a key pitfall in our study. This lack of power will be overcome
by performing behavioural and histological analyses on additional rats. Optimal clinical
relevance in models should remain a key point of improvement in studies. Use of a more
translationally relevant stroke model in respect to the nature of lacunar infarcts may be
helpful. As an example, administration of subcortical infarcts at numerous time points or
the administration of microbeads to induce multiple subcortical infarcts at once 130 would
suffice. In general, the use of ET-1 has its drawbacks in that ET-1 is observed to induce
astrogliosis through receptor mediated binding to ETB receptors on astrocytes

70

.Thus,

study of the influence of ET-1 induced stroke size may be confounded by added
astrocytic activity that is independent of stroke influences, particularly in acute stroke
studies. Future studies may aim to utilize an AD rat model with typical hallmarks
observed in AD, including both Aβ and tau pathologies to enhance clinical relevance.
This may be achieved by utilizing a modified APP/PS1 rat developed by Agca and
colleagues, shown to exhibit increased Aβ42, hippocampal neuronal loss, and learning
and memory deficits compared to Agca’s APP21 (F344Tg) rat
APP transgenic rat models including the APPswe/PS1dE9
model

31

58

277

. Utilization of other

or McGill-R-Thy1-APP

, both of which display progressive Aβ pathology may provide avenues for

studying the effect of stroke in a model of advanced AD pathology.
Completion of the current study aims to assess axonal and myelin health of the major
interhemispheric

fiber

bundles,

as

well

as

oligodendrocyte

populations.

Immunohistochemistry for markers of APP, Aβ, CAA, M2 anti-inflammatory subtype
microglia, and mediators of inflammation will aid in better understanding the
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contributions of any apparent APP and Aβ pathology in influencing inflammation and
axonal fiber bundle health. Correlational analyses between measures of executive
function, processing speed, OX6 white matter immunoreactivity and axonal and white
matter health will further aid in rounding our understanding of the roles of APP and
subcortical stroke in influencing behavioural alterations.
A potential pitfall in our study involves the lack of knowledge of the influences of
stroke in the F344Tg at acute time points post-stroke. It may be possible that enhanced
pathology at acute time points may have recovered sufficiently by a chronic time point.
Future investigation of behaviour and pathology in the sub-acute phases (1-2 months)
after stroke to monitor executive deterioration and recovery may be employed to
investigate the acute influences of added risk factors including mutated APP. Assessment
of reactive gliosis, aquaporin-4 channel localization, and Aβ burden in the gray matter
brain parenchymal space would offer valuable contributions in the understanding of acute
changes and the influence of stroke and mutated APP in the process of CSF glymphatic
drainage.
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Section 5: CONCLUSIONS

81

The present study contributes both to the progressing understanding of how
comorbid pathologies interact to alter behaviours, but also offers contributions to the
available breadth of analytical tools for behavioural analysis in operant-based behavioural
flexibility testing. It is suspected that our study has unravelled interesting relationships
between subcortical stroke, white matter and axonal health, and behavioural implications
including behavioural flexibility and processing speed. While aspects of behavioural
flexibility, processing speed and OX6 immunoreactivity in white matter tracts is
significantly influenced in F344Tg rats, the introduction of a subcortical stroke is
observed to have modest additional influences. It is conceivable that OX6 signal in white
matter is indicative of fibre tract injury in which activated microglia act to rid fibre tracts
of degradation products of APP processing, a process enhanced by the need to dispose of
axonal or myelin breakdown products following stroke. This enhanced state of white
matter tract injury, evidenced by increased OX6 signal, may further perturb axonal
conductance causing processing speed deficits, while possibly leading to tract-specific
gray matter degeneration of key neural regions important for higher-order executive
functions and anxiety-related behaviours. This theory may be tested by correlating
measures of executive dysfunction, processing speed, and OX6 immunoreactivity. These
relationships may help us better understand the contributing roles of interacting micropathologies in influencing cognitive and behavioural changes in the elderly human
populations with prodromal AD. Having single or recurrent strokes, as observed in small
vessel disease, combined with the propensity to process APP and deposit Aβ, as seen in
AD, may in fact lead to poorer axonal and white matter health resulting in loss of
structural and functional connectivity between neural regions. In turn, more profound
behavioural changes may be manifested, contributing to worsening chronic post-stroke
cognitive impairments. A reliable understanding of the contributing pathological roles in
combined AD and stroke may lead to adoption of therapies including anti-inflammatory
and anti-amyloid agents to prevent chronic and persistent white matter injury in an effort
to preserve cognitive functions.
In the development of a pre-clinical model of comorbid stroke and AD, our study
strived to capitalize on relevancies to clinical scenarios. Use of clinically relevant models
of stroke and AD in our study highlighted this importance. To enhance the predictive
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validity of the models in question, important considerations made include the use of aged
animals and assessment of cognitive performances at a chronic time point following
stroke. Chronic time points for assessing dysfunction will model time points used to
assess true patient populations in post-stroke clinical evaluations. A continued spatialtemporal evaluation of post-stroke behavioural and pathological changes in the F344Tg
rat will aid in paving the way for future use of therapeutic intervention in this combined
model. Future studies may aim to optimize clinical relevance for therapeutic studies by
combining other factors typically observed in elderly and diseased populations, including
vascular risk factors such as hypertension or type II Diabetes, inflammatory mediators
typical of the mentioned diseases, and other comorbid factors. This tactic will aid in
making interventional studies and their findings more impactful, relevant, and
translational. These future studies hold tremendous clinical importance.
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